<article title='Antibody'><paragraph><template><target>Redirect</target><arg>Immunoglobulin</arg><arg>the immunoglobulin family</arg><arg>Immunoglobulin superfamily</arg></template><template><target>about</target><arg>the class of proteins</arg></template><link><target>File:Antibody.svg</target><part>thumb</part><part>255px</part><part>Each antibody binds to a specific<space/><link><target>antigen</target></link>; an interaction similar to a lock and key.</part></link></paragraph><paragraph>An<space/><bold>antibody</bold><space/>(Ab), also known as an<space/><bold>immunoglobulin</bold><space/>(Ig), is a large, Y-shape<space/><link><target>protein</target></link><space/>produced by<space/><link><target>plasma cell</target><trail>s</trail></link><space/>that is used by the<space/><link><target>immune system</target></link><space/>to identify and neutralize pathogens such as<space/><link><target>bacterium</target><part>bacteria</part></link><space/>and<space/><link><target>virus</target><trail>es</trail></link>. The antibody recognizes a unique molecule of the harmful agent, called an<space/><link><target>antigen</target></link>, via the variable region.<extension extension_name='ref' name="Janeway5"><template><target>cite book</target><arg name="author">Charles Janeway<space/></arg><arg name="title"><space/>Immunobiology.<space/></arg><arg name="edition"><space/>5th<space/></arg><arg name="publisher"><space/>Garland Publishing<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="id"><space/>[http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call</arg><arg name="isbn"><space/>0-8153-3642-X<space/></arg></template></extension><extension extension_name='ref' name="pmid8450761"><template><target>cite journal</target><arg name="author">Litman GW, Rast JP, Shamblott MJ, Haire RN, Hulst M, Roess W, Litman RT, Hinds-Frey KR, Zilch A, Amemiya CT<space/></arg><arg name="title"><space/>Phylogenetic diversification of immunoglobulin genes and the antibody repertoire<space/></arg><arg name="journal"><space/>Mol. Biol. Evol.<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>60–72<space/></arg><arg name="date">January 1993<space/></arg><arg name="pmid"><space/>8450761</arg></template></extension><space/>Each tip of the &quot;Y&quot; of an antibody contains a<space/><link><target>paratope</target></link><space/>(analogous to a lock) that is specific for one particular<space/><link><target>epitope</target></link><space/>(similarly analogous to a key) on an antigen, allowing these two structures to bind together with precision. Using this binding mechanism, an antibody can<space/><italics>tag</italics><space/>a<space/><link><target>microbe</target></link><space/>or an infected cell for attack by other parts of the immune system, or can neutralize its target directly (for example, by blocking a part of a microbe that is essential for its invasion and survival). The ability of an antibody to communicate with the other components of the immune system is mediated via its Fc region (located at the base of the &quot;Y&quot;), which contains a conserved<space/><link><target>glycosylation</target></link><space/>site involved in these interactions.<extension extension_name='ref' name="immune_glycan"></extension><space/>The production of antibodies is the main function of the<space/><link><target>humoral immune system</target></link>.<extension extension_name='ref' name="Pier"><template><target>cite book</target><arg name="author"><space/>Pier GB, Lyczak JB, Wetzler LM<space/></arg><arg name="title"><space/>Immunology, Infection, and Immunity<space/></arg><arg name="publisher"><space/>ASM Press</arg><arg name="year"><space/>2004<space/></arg><arg name="isbn"><space/>1-55581-246-5</arg></template></extension></paragraph><paragraph>Antibodies are secreted by cells of the adaptive immune system (<link><target>B cells</target></link>), and more specifically, differentiated B cells called<space/><link><target>plasma cells</target></link>. Antibodies can occur in two physical forms, a soluble form that is secreted from the cell, and a<space/><link><target>cell membrane</target><part>membrane</part></link>-bound form that is attached to the surface of a<space/><link><target>B cell</target></link><space/>and is referred to as the B cell receptor (BCR). The BCR is found only on the surface of B cells and facilitates the activation of these cells and their subsequent differentiation into either antibody factories called<space/><link><target>plasma cell</target><trail>s</trail></link><space/>or<space/><link><target>memory B cell</target><trail>s</trail></link><space/>that will survive in the body and remember that same antigen so the B cells can respond faster upon future exposure.<extension extension_name='ref' name="pmid17337763"><template><target>cite journal</target><arg name="author"><space/>Borghesi L, Milcarek C<space/></arg><arg name="title"><space/>From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion<space/></arg><arg name="journal"><space/>Immunol. Res.<space/></arg><arg name="volume"><space/>36<space/></arg><arg name="issue"><space/>1–3<space/></arg><arg name="pages"><space/>27–32<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>17337763<space/></arg><arg name="doi"><space/>10.1385/IR:36:1:27<space/></arg></template></extension><space/>In most cases, interaction of the B cell with a<space/><link><target>T cell</target><part>T helper cell</part></link><space/>is necessary to produce full activation of the B cell and, therefore, antibody generation following antigen binding.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1146/annurev.iy.11.040193.001555<space/></arg><arg name="author">Parker D<space/></arg><arg name="title">T cell-dependent B cell activation<space/></arg><arg name="journal">Annu Rev Immunol<space/></arg><arg name="volume">11<space/></arg><arg name="issue"><space/>1</arg><arg name="pages">331–360<space/></arg><arg name="year">1993<space/></arg><arg name="pmid">8476565</arg></template></extension><space/>Soluble antibodies are released into the<space/><link><target>blood</target></link><space/>and tissue fluids, as well as many<space/><link><target>secretion</target><trail>s</trail></link><space/>to continue to survey for invading microorganisms.</paragraph><paragraph>Antibodies are<space/><link><target>glycoprotein</target><trail>s</trail></link><space/>belonging to the<space/><link><target>immunoglobulin superfamily</target></link>;<extension extension_name='ref' name="immune_glycan"></extension><space/>the terms<space/><italics>antibody</italics><space/>and<space/><italics>immunoglobulin</italics><space/>are often used interchangeably.<extension extension_name='ref' name="Rhoades"><template><target>cite book</target><arg name="author">Rhoades RA, Pflanzer RG<space/></arg><arg name="title"><space/>Human Physiology<space/></arg><arg name="edition"><space/>4th<space/></arg><arg name="publisher"><space/>Thomson Learning<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="isbn"><space/>0-534-42174-1</arg></template></extension><space/>Though strictly speaking, an antibody is not the same as an immunoglobulin; B cells can produce two types of immunoglobulins - surface immunoglobulins, which are B cell receptors; and secreted immunoglobulins, which are antibodies. So antibodies are one of two classes of immunoglobulins. Antibodies are typically made of basic structural unitseach with two large<space/><link><target>heavy chain</target><trail>s</trail></link><space/>and two small<space/><link><target>Immunoglobulin light chain</target><part>light chains</part></link>. There are several different types of antibody heavy chains based on five different types of crystallisable fragments (Fc) that may be attached to the antigen-binding fragments. The five different types of Fc regions allow antibodies to be grouped into five<space/><italics><link><target>isotype (immunology)</target><part>isotypes</part></link></italics>. Each Fc region of a particular antibody isotype is able to bind to its specific Fc Receptor (except for IgD, which is essentially the BCR), thus allowing the antigen-antibody complex to mediate different roles depending on which FcR it binds. The ability of an antibody to bind to its corresponding FcR is further modulated by the structure of the glycan(s) present at conserved sites within its Fc region.<extension extension_name='ref' name="immune_glycan"></extension><space/>The ability of antibodies to bind to FcRs helps to direct the appropriate immune response for each different type of foreign object they encounter.<extension extension_name='ref' name="Market"><template><target>cite journal</target><arg name="author"><space/>Market E, Papavasiliou FN<space/></arg><arg name="title"><space/>V(D)J recombination and the evolution of the adaptive immune system<space/></arg><arg name="journal"><space/>PLoS Biol.<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>E16<space/></arg><arg name="date">October 2003<space/></arg><arg name="pmid"><space/>14551913<space/></arg><arg name="pmc"><space/>212695<space/></arg><arg name="doi"><space/>10.1371/journal.pbio.0000016<space/></arg></template></extension><space/>For example,<space/><link><target>IgE</target></link><space/>is responsible for an<space/><link><target>allergic</target></link><space/>response consisting of<space/><link><target>mast cell</target></link><space/>degranulation and<space/><link><target>histamine</target></link><space/>release. IgE's Fab paratope binds to allergic<space/><link><target>antigen</target></link>, for example<space/><link><target>house dust mite</target></link><space/>particles, while its Fc region binds to Fc receptor . The allergen-IgE-FcR interaction mediates allergic signal transduction to induce conditions such as asthma.<space/></paragraph><paragraph>Though the general structure of all antibodies is very similar, a small region at the tip of the protein is extremely variable, allowing millions of antibodies with slightly different tip structures, or antigen-binding sites, to exist. This region is known as the<space/><italics>hypervariable region</italics>. Each of these variants can bind to a different antigen.<extension extension_name='ref' name="Janeway5"><template><target>cite book</target><arg name="author"><space/>Charles Janeway<space/></arg><arg name="title"><space/>Immunobiology.<space/></arg><arg name="edition"><space/>5th<space/></arg><arg name="publisher"><space/>Garland Publishing<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="url"><space/>http://www.ncbi.nlm.nih.gov/books/NBK10757/<space/></arg><arg name="isbn"><space/>978-0-8153-3642-6<space/></arg></template></extension><space/>This enormous diversity of antibody paratopes on the antigen-binding fragments allows the immune system to recognize an equally wide variety of antigens.<extension extension_name='ref' name="Rhoades"><template><target>cite book</target><arg name="author">Rhoades RA, Pflanzer RG<space/></arg><arg name="title"><space/>Human Physiology</arg><arg name="edition"><space/>4th<space/></arg><arg name="publisher"><space/>Thomson Learning<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="isbn"><space/>978-0-534-42174-8</arg></template></extension><space/>The large and diverse population of antibody paratope is generated by random recombination events of a set of<space/><link><target>gene</target></link><space/>segments that encode different antigen-binding sites (or<space/><italics>paratopes</italics>), followed by random<space/><link><target>mutation</target><trail>s</trail></link><space/>in this area of the antibody gene, which create further diversity.<extension extension_name='ref' name="Market"></extension><extension extension_name='ref' name="diaz"><template><target>cite journal</target><arg name="author">Diaz M, Casali P<space/></arg><arg name="title">Somatic immunoglobulin hypermutation<space/></arg><arg name="journal">Curr Opin Immunol<space/></arg><arg name="volume">14<space/></arg><arg name="issue">2<space/></arg><arg name="pages">235–240<space/></arg><arg name="year">2002<space/></arg><arg name="pmid">11869898<space/></arg><arg name="doi">10.1016/S0952-7915(02)00327-8</arg></template></extension><space/>This recombinational process that produces clonal antibody paratope diversity is called V(D)J or VJ recombination. Basically, the antibody paratope is polygenic, made up of three genes, V, D, and J. Each paratope locus is also polymorphic, such that during antibody production, one allele of V, one of D, and one of J is chosen. These gene segments are then joined together using random genetic recombination to produce the paratope. The regions where the genes are randomly recombined together is the hyper variable region used to recognise different antigens on a clonal basis.<space/></paragraph><paragraph>Antibody genes also re-organize in a process called<space/><link><target>Immunoglobulin class switching</target><part>class switching</part></link><space/>that changes the one type of heavy chain Fc fragment to another, creating a different isotype of the antibody that retains the antigen-specific variable region. This allows a single antibody to be used by different types of Fc receptors, expressed on different parts of the immune system.</paragraph><heading level='2'>Forms</heading><paragraph>The membrane-bound form of an antibody may be called a<space/><italics>surface immunoglobulin</italics><space/>(sIg) or a<space/><italics>membrane immunoglobulin</italics><space/>(mIg). It is part of the<space/><italics>B cell receptor</italics><space/>(BCR), which allows a B cell to detect when a specific antigen is present in the body and triggers B cell activation.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Parker D</arg><arg name="title">T cell-dependent B cell activation</arg><arg name="journal">Annu. Rev. Immunol.</arg><arg name="volume">11</arg><arg name="issue">1</arg><arg name="pages">331–360</arg><arg name="year">1993</arg><arg name="pmid">8476565</arg><arg name="doi">10.1146/annurev.iy.11.040193.001555</arg></template></extension><space/>The BCR is composed of surface-bound IgD or IgM antibodies and associated Ig- and Ig-<space/><link><target>heterodimer</target><trail>s</trail></link>, which are capable of<space/><link><target>signal transduction</target></link>.<extension extension_name='ref' name="Wintrobe"><template><target>cite book</target><arg name="author">Wintrobe, Maxwell Myer</arg><arg name="authorlink"><space/>Maxwell Wintrobe</arg><arg name="editor">John G. Greer, John Foerster, John N Lukens, George M Rodgers, Frixos Paraskevas</arg><arg name="title">Wintrobe's clinical hematology</arg><arg name="edition">11</arg><arg name="publisher">Lippincott Williams & Wilkins</arg><arg name="location">Hagerstown, MD</arg><arg name="year">2004</arg><arg name="pages">453–456</arg><arg name="isbn">978-0-7817-3650-3</arg></template></extension><space/>A typical human B cell will have 50,000 to 100,000 antibodies bound to its surface.<extension extension_name='ref' name="Wintrobe"></extension><space/>Upon antigen binding, they cluster in large patches, which can exceed 1 micrometer in diameter, on lipid rafts that isolate the BCRs from most other cell signaling receptors.<extension extension_name='ref' name="Wintrobe"></extension>These patches may improve the efficiency of the<space/><link><target>Cell-mediated immunity</target><part>cellular immune response</part></link>.<extension extension_name='ref' name="pmid18275475"><template><target>cite journal</target><arg name="author">Tolar P, Sohn HW, Pierce SK</arg><arg name="title">Viewing the antigen-induced initiation of B-cell activation in living cells</arg><arg name="journal">Immunol. Rev.</arg><arg name="volume">221</arg><arg name="issue">1</arg><arg name="pages">64–76</arg><arg name="date">February 2008</arg><arg name="pmid">18275475</arg><arg name="doi">10.1111/j.1600-065X.2008.00583.x</arg><arg name="url">http://www.blackwell-synergy.com/openurl?genre</arg></template></extension><space/>In humans, the cell surface is bare around the B cell receptors for several hundred nanometers,<extension extension_name='ref' name="Wintrobe"></extension><space/>which further isolates the BCRs from competing influences.</paragraph><heading level='2'>Antibodyantigen interactions</heading><paragraph>The antibody's paratope interacts with the antigen's epitope. An antigen usually contains different epitopes along its surface arranged discontinuously, and dominant epitopes on a given antigen are called determinants.<space/></paragraph><paragraph>Antibody and antigen interact by spatial complementarity (lock and key). The molecular forces involved in the Fab-epitope interaction are weak and non-specific - for example<space/><link><target>Coulomb's law</target><part>electrostatic forces</part></link>,<space/><link><target>hydrogen bonds</target></link>,<space/><link><target>hydrophobic interactions</target></link>, and<space/><link><target>van der Waals force</target><trail>s</trail></link>. This means binding between antibody and antigen is reversible, and the antibody's<space/><link><target>Affinity (pharmacology)</target><part>affinity</part></link><space/>towards an antigen is relative rather than absolute. Relatively weak binding also means it is possible for an antibody to cross-react with different antigens of different relative affinities.</paragraph><heading level='2'>Isotypes</heading><paragraph>Antibodies can come in different varieties known as<space/><link><target>Isotype (immunology)</target><part>isotypes</part></link><space/>or classes. In<space/><link><target>eutheria</target><part>placental</part></link><space/>mammals there are five antibody isotypes known as IgA, IgD, IgE, IgG, and IgM. They are each named with an &quot;Ig&quot; prefix that stands for immunoglobulin, a name sometimes used interchangeably with antibody, and differ in their biological properties, functional locations and ability to deal with different antigens, as depicted in the table.<extension extension_name='ref' name="woof"><template><target>cite journal</target><arg name="author">Woof J, Burton D<space/></arg><arg name="title">Human antibody-Fc receptor interactions illuminated by crystal structures.<space/></arg><arg name="journal">Nat Rev Immunol<space/></arg><arg name="volume">4<space/></arg><arg name="issue">2<space/></arg><arg name="pages">89–99<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">15040582<space/></arg><arg name="doi">10.1038/nri1266</arg></template></extension><space/>The different suffixes of the antibody isotypes denote the different types of heavy chains the antibody contains, with each heavy chain class named alphabetically: , , , , and . This gives rise to IgA, IgG, IgD, IgE, and IgM, respectively.<space/></paragraph><table class="wikitable" style="width:100%; float:right; font-size:90%; margin-left:15px"><tablecaption>Antibody isotypes of mammals</tablecaption><tablerow><tablehead>Name</tablehead><tablecell>Types</tablecell><tablecell style="text-align:center;">Description</tablecell><tablecell style="text-align:center;">Antibody complexes</tablecell></tablerow><tablerow><tablecell style="text-align:center;"><link><target>IgA</target></link></tablecell><tablecell style="text-align:center;">2</tablecell><tablecell>Found in<space/><link><target>mucosal</target></link><space/>areas, such as the<space/><link><target>Gut (zoology)</target><part>gut</part></link>,<space/><link><target>respiratory tract</target></link><space/>and<space/><link><target>urogenital tract</target></link>, and prevents colonization by<space/><link><target>pathogen</target><trail>s</trail></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Underdown B, Schiff J<space/></arg><arg name="title">Immunoglobulin A: strategic defense initiative at the mucosal surface<space/></arg><arg name="journal">Annu Rev Immunol<space/></arg><arg name="volume">4<space/></arg><arg name="issue"><space/>1</arg><arg name="pages">389–417<space/></arg><arg name="year">1986<space/></arg><arg name="pmid">3518747<space/></arg><arg name="doi">10.1146/annurev.iy.04.040186.002133</arg></template></extension><space/>Also found in saliva, tears, and breast milk.</tablecell><tablecell rowspan="5"><link><target>File:Mono-und-Polymere.svg</target><part>170px</part><part>Some antibodies form<space/><link><target>protein structure</target><part>complexes</part></link><space/>that bind to multiple antigen molecules.</part></link></tablecell></tablerow><tablerow><tablecell style="text-align:center;"><link><target>IgD</target></link></tablecell><tablecell style="text-align:center;">1</tablecell><tablecell>Functions mainly as an<space/><link><target>antigen</target></link><space/>receptor on B cells that have not been exposed to antigens.<extension extension_name='ref' name="Geisberger"><template><target>cite journal</target><arg name="author">Geisberger R, Lamers M, Achatz G<space/></arg><arg name="title">The riddle of the dual expression of IgM and IgD<space/></arg><arg name="journal">Immunology<space/></arg><arg name="volume">118<space/></arg><arg name="issue">4<space/></arg><arg name="pages">889–898<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16895553<space/></arg><arg name="doi">10.1111/j.1365-2567.2006.02386.x<space/></arg><arg name="pmc">1782314</arg></template></extension><space/>It has been shown to activate<space/><link><target>basophils</target></link><space/>and<space/><link><target>mast cells</target></link><space/>to produce<space/><link><target>antimicrobial</target></link><space/>factors.<extension extension_name='ref' name="Chen"><template><target>cite journal</target><arg name="author">Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, Edholm ES, Santini PA, Rath P, Chiu A, Cattalini M, Litzman J, B Bussel J, Huang B, Meini A, Riesbeck K, Cunningham-Rundles C, Plebani A, Cerutti A<space/></arg><arg name="title">Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils<space/></arg><arg name="journal">Nature Immunology<space/></arg><arg name="volume">10<space/></arg><arg name="issue">8<space/></arg><arg name="pages">889–898<space/></arg><arg name="year">2009<space/></arg><arg name="pmid">19561614<space/></arg><arg name="doi">10.1038/ni.1748<space/></arg><arg name="pmc">2785232</arg></template></extension></tablecell></tablerow><tablerow><tablecell style="text-align:center;"><link><target>IgE</target></link></tablecell><tablecell style="text-align:center;">1</tablecell><tablecell>Binds to<space/><link><target>allergens</target></link><space/>and triggers<space/><link><target>histamine</target></link><space/>release from<space/><link><target>mast cells</target></link><space/>and<space/><link><target>basophil</target><trail>s</trail></link>, and is involved in<space/><link><target>allergy</target></link>. Also protects against<space/><link><target>parasitic worm</target><trail>s</trail></link>.<extension extension_name='ref' name="Pier"></extension></tablecell></tablerow><tablerow><tablecell style="text-align:center;"><link><target>IgG</target></link></tablecell><tablecell style="text-align:center;">4</tablecell><tablecell>In its four forms, provides the majority of antibody-based immunity against invading pathogens.<extension extension_name='ref' name="Pier"></extension><space/>The only antibody capable of crossing the<space/><link><target>placenta</target></link><space/>to give passive immunity to the<space/><link><target>fetus</target></link>.</tablecell></tablerow><tablerow><tablecell style="text-align:center;"><link><target>IgM</target></link></tablecell><tablecell style="text-align:center;">1</tablecell><tablecell>Expressed on the surface of B cells (monomer) and in a secreted form (pentamer) with very high<space/><link><target>avidity</target></link>. Eliminates pathogens in the early stages of B cell-mediated (humoral) immunity before there is sufficient IgG.<extension extension_name='ref' name="Pier"></extension><extension extension_name='ref' name="Geisberger"></extension></tablecell></tablerow></table><paragraph>The antibody isotype of a<space/><link><target>B cell</target></link><space/>changes during cell<space/><link><target>Pre-pre B cell</target><part>development</part></link><space/>and activation. Immature B cells, which have never been exposed to an antigen, express only the IgM+ isotype in a cell surface bound form. The B lymphocyte, in this ready-to-respond form, is known as a &quot;naive B lymphocyte.&quot; The naive B lymphocyte expresses both surface IgM+ and IgD+. The co-expression of both of these immunoglobulin isotypes renders the B cell ready to respond to antigen.<extension extension_name='ref' name="Goding"><template><target>cite journal</target><arg name="author">Goding J<space/></arg><arg name="title">Allotypes of IgM and IgD receptors in the mouse: a probe for lymphocyte differentiation<space/></arg><arg name="journal">Contemp Top Immunobiol<space/></arg><arg name="volume">8<space/></arg><arg name="pages">203–43<space/></arg><arg name="year"><space/>1978</arg><arg name="pmid">357078<space/></arg><arg name="doi">10.1007/978-1-4684-0922-2_7<space/></arg><arg name="isbn">978-1-4684-0924-6</arg></template></extension><space/>B cell activation follows engagement of the cell-bound antibody molecule with an antigen, causing the cell to divide and<space/><link><target>Cellular differentiation</target><part>differentiate</part></link><space/>into an antibody-producing cell called a<space/><link><target>plasma cell</target></link>. In this activated form, the B cell starts to produce antibody in a<space/><link><target>secrete</target><trail>d</trail></link><space/>form rather than a<space/><link><target>cell membrane</target><part>membrane</part></link>-bound form. Some<space/><link><target>daughter cell</target><trail>s</trail></link><space/>of the activated B cells undergo<space/><link><target>isotype switching</target></link>, a mechanism that causes the production of antibodies to change from IgM or IgD to the other antibody isotypes, IgE, IgA, or IgG, that have defined roles in the immune system.</paragraph><table class="wikitable"><tablecaption>Antibody isotypes not found in mammals</tablecaption><tablerow><tablehead>Name</tablehead><tablehead>Types</tablehead><tablehead>Description</tablehead></tablerow><tablerow><tablecell><link><target>Immunoglobulin Y</target><part>IgY</part></link></tablecell><tablecell></tablecell><tablecell><link><target>Bird</target><trail>s</trail></link><space/>and<space/><link><target>reptile</target><trail>s</trail></link>.<xhtml:br></xhtml:br>Found in<space/><link><target>Serum (blood)</target><part>serum</part></link><space/>and<space/><link><target>egg yolk</target></link>.</tablecell></tablerow><tablerow><tablecell>IgW</tablecell><tablecell></tablecell><tablecell>Found in<space/><link><target>Elasmobranchii</target><part>sharks and skates</part></link>; related to mammalian IgD.<extension extension_name='ref'><template><target>cite journal</target><arg name="last"><space/>Berstein<space/></arg><arg name="first">RM<space/></arg><arg name="last2"><space/>Schluter<space/></arg><arg name="first2">SF<space/></arg><arg name="last3"><space/>Shen<space/></arg><arg name="first3">S<space/></arg><arg name="last4"><space/>Marchalonis<space/></arg><arg name="first4">JJ<space/></arg><arg name="title"><space/>A new high molecular weight immunoglobulin class from the carcharhine shark: implications for the properties of the primordial immunoglobulin.<space/></arg><arg name="journal"><space/>Proc Natl Acad Sci U S A.<space/></arg><arg name="volume">93<space/></arg><arg name="issue">8<space/></arg><arg name="pages">3289–3293<space/></arg><arg name="date"><space/>1996-04-16<space/></arg><arg name="doi"><space/>10.1073/pnas.93.8.3289</arg><arg name="id"><space/></arg><arg name="accessdate"><space/>2014-04-15<space/></arg><arg name="pmid">8622930</arg></template></extension></tablecell></tablerow></table><heading level='2'>Structure</heading><paragraph>Antibodies are heavy (~150&amp;nbsp;k<link><target>Dalton (unit)</target><part>Da</part></link>)<space/><link><target>globular protein</target><part>globular</part></link><space/><link><target>plasma protein</target><trail>s</trail></link>. They have sugar chains (glycans) added to conserved<space/><link><target>amino acid</target></link><space/>residues.<extension extension_name='ref' name="immune_glycan"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Mattu T, Pleass R, Willis A, Kilian M, Wormald M, Lellouch A, Rudd P, Woof J, Dwek R<space/></arg><arg name="title">The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions<space/></arg><arg name="journal">J Biol Chem<space/></arg><arg name="volume">273<space/></arg><arg name="issue">4<space/></arg><arg name="pages">2260–2272<space/></arg><arg name="year">1998<space/></arg><arg name="pmid">9442070<space/></arg><arg name="doi">10.1074/jbc.273.4.2260</arg></template></extension><space/>In other words, antibodies are<space/><italics><link><target>glycoprotein</target><trail>s</trail></link></italics>.<extension extension_name='ref' name="immune_glycan"></extension><space/>The attached glycans are critically important to the structure and function of the antibody.<extension extension_name='ref' name="immune_glycan"></extension><space/>Among other things the expressed glycans can modulate an antibody's affinity for its corresponding FcR(s).<extension extension_name='ref' name="immune_glycan"></extension><space/></paragraph><paragraph>The basic functional unit of each antibody is an immunoglobulin (Ig)<space/><link><target>monomer</target></link><space/>(containing only one Ig unit); secreted antibodies can also be<space/><link><target>protein dimer</target><part>dimeric</part></link><space/>with two Ig units as with IgA,<space/><link><target>tetramer protein</target><part>tetrameric</part></link><space/>with four Ig units like<space/><link><target>teleost fish</target></link><space/>IgM, or<space/><link><target>pentamer</target><trail>ic</trail></link><space/>with five Ig units, like mammalian IgM.<extension extension_name='ref' name="roux"><template><target>cite journal</target><arg name="author">Roux K<space/></arg><arg name="title">Immunoglobulin structure and function as revealed by electron microscopy<space/></arg><arg name="journal">Int Arch Allergy Immunol<space/></arg><arg name="volume">120<space/></arg><arg name="issue">2<space/></arg><arg name="pages">85–99<space/></arg><arg name="year">1999<space/></arg><arg name="pmid">10545762<space/></arg><arg name="doi">10.1159/000024226</arg></template></extension><link><target>File:Antibody IgG2.png</target><part>thumb</part><part>right</part><part>Several immunoglobulin domains make up the two heavy chains (red and blue) and the two light chains (green and yellow) of an antibody. The immunoglobulin domains are composed of between 7 (for constant domains) and 9 (for variable domains)<space/><link><target>-strand</target><trail>s</trail></link>.</part></link><space/>The variable parts of an antibody are its V regions, and the constant part is its C region.</paragraph><heading level='3'>Immunoglobulin domains</heading><paragraph>The Ig monomer is a &quot;Y&quot;-shaped molecule that consists of four<space/><link><target>polypeptide</target></link><space/>chains; two identical<space/><italics>heavy chains</italics><space/>and two identical<space/><italics>light chains</italics><space/>connected by<space/><link><target>disulfide bond</target><trail>s</trail></link>.<extension extension_name='ref' name="woof"></extension>Each chain is composed of<space/><link><target>structural domain</target><trail>s</trail></link><space/>called<space/><link><target>immunoglobulin domain</target><trail>s</trail></link>. These domains contain about 70110<space/><link><target>amino acid</target><trail>s</trail></link><space/>and are classified into different categories (for example, variable or IgV, and constant or IgC) according to their size and function.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Barclay A<space/></arg><arg name="title">Membrane proteins with immunoglobulin-like domains – a master superfamily of interaction molecules<space/></arg><arg name="journal">Semin Immunol<space/></arg><arg name="volume">15<space/></arg><arg name="issue">4<space/></arg><arg name="pages">215–223<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">14690046<space/></arg><arg name="doi">10.1016/S1044-5323(03)00047-2</arg></template></extension><space/>They have a characteristic<space/><link><target>immunoglobulin fold</target></link><space/>in which two<space/><link><target>beta sheet</target><trail>s</trail></link><space/>create a &quot;sandwich&quot; shape, held together by interactions between conserved<space/><link><target>cysteine</target><trail>s</trail></link><space/>and other charged amino acids.</paragraph><heading level='3'>Heavy chain</heading><paragraph><template><target>details</target><arg>Immunoglobulin heavy chain</arg></template>There are five types of mammalian Ig<space/><link><target>Immunoglobulin heavy chain</target><part>heavy chain</part></link><space/>denoted by the<space/><link><target>Greek letters</target></link>:<space/><link><target></target></link>,<space/><link><target></target></link>,<space/><link><target></target></link>,<space/><link><target></target></link>, and<space/><link><target></target></link>.<extension extension_name='ref' name="Janeway5"></extension><space/>The type of heavy chain present defines the<space/><italics>class</italics><space/>of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.<extension extension_name='ref' name="Rhoades"></extension><space/>Distinct heavy chains differ in size and composition; and contain approximately 450 amino acids, whereas and have approximately 550<space/><link><target>amino acid</target><trail>s</trail></link>.<extension extension_name='ref' name="Janeway5"></extension><link><target>File:Immunoglobulin basic unit.svg</target><part>thumb</part><part>1.<space/><link><target>Fragment antigen binding</target><part>Fab region</part></link><xhtml:br></xhtml:br>2.<space/><link><target>Fragment crystallizable region</target><part>Fc region</part></link><xhtml:br></xhtml:br>3.<space/><link><target>Immunoglobulin heavy chain</target><part>Heavy chain</part></link><space/>(blue) with one variable (V<xhtml:sub>H</xhtml:sub>) domain followed by a constant domain (C<xhtml:sub>H</xhtml:sub>1), a hinge region, and two more constant (C<xhtml:sub>H</xhtml:sub>2 and C<xhtml:sub>H</xhtml:sub>3) domains.<xhtml:br></xhtml:br>4.<space/><link><target>Immunoglobulin light chain</target><part>Light chain</part></link><space/>(green) with one variable (V<xhtml:sub>L</xhtml:sub>) and one constant (C<xhtml:sub>L</xhtml:sub>) domain<xhtml:br></xhtml:br>5. Antigen binding site (paratope)<xhtml:br></xhtml:br>6. Hinge regions.</part></link></paragraph><paragraph>In<space/><link><target>bird</target><trail>s</trail></link>, the major serum antibody, also found in yolk, is called<space/><link><target>Immunoglobulin Y</target><part>IgY</part></link>. It is quite different from mammalian IgG. However, in some older literature and even on some commercial life sciences product websites it is still called &quot;IgG&quot;, which is incorrect and can be confusing.</paragraph><paragraph>Each heavy chain has two regions, the<space/><italics>constant region</italics><space/>and the<space/><italics>variable region</italics>. The constant region is identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains , and have a constant region composed of<space/><italics>three</italics><space/>tandem (in a line) Ig<space/><link><target>Structural domain</target><part>domains</part></link>, and a hinge region for added flexibility;<extension extension_name='ref' name="woof"></extension><space/>heavy chains and have a constant region composed of<space/><italics>four</italics><space/>immunoglobulin domains.<extension extension_name='ref' name="Janeway5"></extension><space/>The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or<space/><link><target>Clone (B-cell biology)</target><part>B cell clone</part></link>. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.</paragraph><heading level='3'>Light chain</heading><paragraph><template><target>details</target><arg>Immunoglobulin light chain</arg></template>In mammals there are two types of<space/><link><target>immunoglobulin light chain</target></link>, which are called<space/><link><target>lambda</target></link><space/>() and<space/><link><target>kappa</target></link><space/>().<extension extension_name='ref' name="Janeway5"></extension><space/>A light chain has two successive domains: one constant domain and one variable domain. The approximate length of a light chain is 211 to 217 amino acids.<extension extension_name='ref' name="Janeway5"></extension><space/>Each antibody contains two light chains that are always identical; only one type of light chain, or , is present per antibody in mammals. Other types of light chains, such as the<space/><link><target>iota</target></link><space/>() chain, are found in other<space/><link><target>vertebrate</target><trail>s</trail></link><space/>like sharks (<link><target>Chondrichthyes</target></link>) and bony fishes (<link><target>Teleostei</target></link>).</paragraph><heading level='3'><template><target>anchor</target><arg>CDRs, Fv, Fab and Fc Regions</arg></template>CDRs, Fv, Fab and Fc regions</heading><preblock><preline></preline></preblock><paragraph>Some parts of an antibody have the same functions. The arms of the Y, for example, contain the sites that can bind to antigens (in general, identical) and, therefore, recognize specific foreign objects. This region of the antibody is called the<space/><italics><link><target>Fab region</target><part>Fab (fragment, antigen-binding) region</part></link></italics>. It is composed of one constant and one variable domain from each heavy and light chain of the antibody.<extension extension_name='ref' name="putnam79"><template><target>cite journal</target><arg name="author">Putnam FW, Liu YS, Low TL<space/></arg><arg name="title">Primary structure of a human IgA1 immunoglobulin. IV. Streptococcal IgA1 protease, digestion, Fab and Fc fragments, and the complete amino acid sequence of the alpha 1 heavy chain</arg><arg name="journal"><space/>J Biol Chem</arg><arg name="volume">254<space/></arg><arg name="issue">8<space/></arg><arg name="pages">2865–74</arg><arg name="year">1979<space/></arg><arg name="pmid">107164</arg></template></extension>The<space/><link><target>paratope</target></link><space/>is shaped at the<space/><link><target>N-terminal end</target><part>amino terminal end</part></link><space/>of the antibody<space/><link><target>monomer</target></link><space/>by the variable domains from the heavy and light chains. The variable domain is also referred to as the F<xhtml:sub>V</xhtml:sub><space/>region and is the most important region for binding to antigens. To be specific, variable loops of -strands, three each on the light (V<xhtml:sub>L</xhtml:sub>) and heavy (V<xhtml:sub>H</xhtml:sub>) chains are responsible for binding to the antigen. These loops are referred to as the<space/><link><target>complementarity determining region</target><trail>s</trail></link><space/>(CDRs).The structures of these CDRs have been clustered and classified by Chothia et al.<extension extension_name='ref' name="Chothia1997"><template><target>cite journal</target><arg name="doi">10.1006/jmbi.1997.1354</arg><arg name="author">Al-Lazikani B, Lesk AM, Chothia C</arg><arg name="title">Standard conformations for the canonical structures of immunoglobulins</arg><arg name="journal"><space/>J Mol Biol</arg><arg name="volume">273</arg><arg name="issue">4</arg><arg name="pages">927–948</arg><arg name="year">1997</arg><arg name="pmid">9367782</arg></template></extension>and more recently by North et al.<extension extension_name='ref' name="North2010"><template><target>cite journal</target><arg name="author">North B, Lehmann A, Dunbrack RL</arg><arg name="title">A new clustering of antibody CDR loop conformations</arg><arg name="journal"><space/>J Mol Biol</arg><arg name="volume">406</arg><arg name="issue">2</arg><arg name="pages">228–256</arg><arg name="year">2010</arg><arg name="pmid">21035459</arg><arg name="doi">10.1016/j.jmb.2010.10.030</arg><arg name="pmc">3065967</arg></template></extension>and Nikoloudis et al.<extension extension_name='ref' name="Nikoloudis2014"><template><target>cite journal</target><arg name="author">Nikoloudis D, Pitts JE, Saldanha JW</arg><arg name="title">A complete, multi-level conformational clustering of antibody complementarity-determining regions</arg><arg name="journal"><space/>PeerJ</arg><arg name="volume">2</arg><arg name="issue">e456</arg><arg name="year">2014</arg><arg name="pmid">25071986</arg><arg name="doi">10.7717/peerj.456</arg><arg name="pmc">4103072</arg></template></extension>In the framework of the<space/><link><target>immune network theory</target></link>, CDRs are also called idiotypes. According to immune network theory, the adaptive immune system is regulated by interactions between idiotypes.</paragraph><paragraph>The base of the Y plays a role in modulating immune cell activity. This region is called the<space/><italics><link><target>Fc region</target><part>Fc (Fragment, crystallizable) region</part></link></italics>, and is composed of two heavy chains that contribute two or three constant domains depending on the class of the antibody.<extension extension_name='ref' name="Janeway5"></extension><space/>Thus, the Fc region ensures that each antibody generates an appropriate immune response for a given antigen, by binding to a specific class of<space/><link><target>Fc receptor</target><trail>s</trail></link>, and other immune molecules, such as<space/><link><target>Complement system</target><part>complement</part></link><space/>proteins. By doing this, it mediates different<space/><link><target>physiological</target></link><space/>effects including recognition of<space/><link><target>opsonization</target><part>opsonized</part></link><space/>particles (binding to FcR),<space/><link><target>lysis</target></link><space/>of cells (binding to complement), and<space/><link><target>degranulation</target></link><space/>of<space/><link><target>mast cells</target></link>,<space/><link><target>basophils</target></link>, and<space/><link><target>eosinophils</target></link><space/>(binding to FcR).<extension extension_name='ref' name="woof"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Heyman B<space/></arg><arg name="title">Complement and Fc-receptors in regulation of the antibody response<space/></arg><arg name="journal">Immunol Lett<space/></arg><arg name="volume">54<space/></arg><arg name="issue">2–3<space/></arg><arg name="pages">195–199<space/></arg><arg name="year">1996<space/></arg><arg name="pmid">9052877<space/></arg><arg name="doi">10.1016/S0165-2478(96)02672-7</arg></template></extension></paragraph><paragraph>In summary, whilst the Fab region of the antibody determines its antigen specificity, the Fc region of the antibody determines the antibody's class effect. Since only the constant domains of the heavy chains make up the Fc region of an antibody, the classes of heavy chain in antibodies determine their class effects. Possible classes of heavy chains in antibodies include alpha, gamma, delta, epsilon, and mu, and they define the antibody's isotypes IgA, G, D, E, and M, respectively. This infers different isotypes of antibodies have different class effects due to their different Fc regions binding and activating different types of receptors. Possible class effects of antibodies include: Opsonisation, agglutination, haemolysis, complement activation, mast cell degranulation, and neutralisation (though this class effect may be mediated by the Fab region rather than the Fc region). It also implies that Fab-mediated effects are directed at microbes or toxins, whilst Fc mediated effects are directed at effector cells or effector molecules (see below).</paragraph><heading level='2'>Function</heading><paragraph><template><target>Further2</target><arg>[[Immune system]]</arg></template>Activated B cells<space/><link><target>cellular differentiation</target><part>differentiate</part></link><space/>into either antibody-producing cells called<space/><link><target>plasma cell</target><trail>s</trail></link><space/>that secrete soluble antibody or<space/><link><target>memory B cell</target><part>memory cells</part></link><space/>that survive in the body for years afterward in order to allow the immune system to remember an antigen and respond faster upon future exposures.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Borghesi L, Milcarek C</arg><arg name="title">From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion</arg><arg name="journal">Immunol Res</arg><arg name="volume">36<space/></arg><arg name="issue">1–3</arg><arg name="pages">27–32</arg><arg name="year">2006<space/></arg><arg name="pmid">17337763</arg><arg name="doi">10.1385/IR:36:1:27</arg></template></extension></paragraph><paragraph>At the<space/><link><target>prenatal</target></link><space/>and neonatal stages of life, the presence of antibodies is provided by<space/><link><target>passive immunization</target></link><space/>from the mother. Early endogenous antibody production varies for different kinds of antibodies, and usually appear within the first years of life. Since antibodies exist freely in the bloodstream, they are said to be part of the<space/><link><target>humoral immune system</target></link>. Circulating antibodies are produced by clonal B cells that specifically respond to only one<space/><link><target>antigen</target></link><space/>(an example is a<space/><link><target>virus</target></link><space/><link><target>capsid</target><part>capsid protein</part></link><space/>fragment). Antibodies contribute to<space/><link><target>immunity (medical)</target><part>immunity</part></link><space/>in three ways: They prevent pathogens from entering or damaging cells by binding to them; they stimulate removal of pathogens by<space/><link><target>macrophages</target></link><space/>and other cells by coating the pathogen; and they trigger destruction of pathogens by stimulating other<space/><link><target>immune response</target><trail>s</trail></link><space/>such as the<space/><link><target>complement system</target><part>complement pathway</part></link>.<extension extension_name='ref' name="Ravetch"><template><target>cite journal</target><arg name="author">Ravetch J, Bolland S<space/></arg><arg name="title">IgG Fc receptors<space/></arg><arg name="journal">Annu Rev Immunol<space/></arg><arg name="volume">19<space/></arg><arg name="issue"><space/>1</arg><arg name="pages">275–290<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11244038<space/></arg><arg name="doi">10.1146/annurev.immunol.19.1.275</arg></template></extension>Antibodies will also trigger vasoactive amine degranulation to contribute to immunity against certain types of antigens (helminths, allergens).<space/></paragraph><paragraph><link><target>File:IgM white background.png</target><part>thumb</part><part>left</part><part>The secreted mammalian<space/><link><target>IgM</target></link><space/>has five Ig units. Each Ig unit (labeled 1) has two epitope binding<space/><link><target>Fab region</target><trail>s</trail></link>, so IgM is capable of binding up to 10 epitopes.</part></link></paragraph><heading level='3'>Activation of complement</heading><paragraph>Antibodies that bind to surface antigens (for example, on bacteria) will attract the first component of the<space/><link><target>complement cascade</target></link><space/>with their<space/><link><target>Fv region</target><part>Fc region</part></link><space/>and initiate activation of the &quot;classical&quot; complement system.<extension extension_name='ref' name="Ravetch"></extension><space/>This results in the killing of bacteria in two ways.<extension extension_name='ref' name="Pier"></extension><space/>First, the binding of the antibody and complement molecules marks the microbe for ingestion by<space/><link><target>phagocyte</target><trail>s</trail></link><space/>in a process called<space/><link><target>opsonization</target></link>; these phagocytes are attracted by certain complement molecules generated in the complement cascade. Second, some complement system components form a<space/><link><target>Complement membrane attack complex</target><part>membrane attack complex</part></link><space/>to assist antibodies to kill the bacterium directly (bacteriolysis).<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Rus H, Cudrici C, Niculescu F<space/></arg><arg name="title">The role of the complement system in innate immunity<space/></arg><arg name="journal">Immunol Res<space/></arg><arg name="volume">33<space/></arg><arg name="issue">2<space/></arg><arg name="pages">103–112<space/></arg><arg name="year">2005<space/></arg><arg name="pmid">16234578<space/></arg><arg name="doi">10.1385/IR:33:2:103</arg></template></extension><space/></paragraph><heading level='3'>Activation of effector cells</heading><paragraph>To combat pathogens that replicate outside cells, antibodies bind to pathogens to link them together, causing them to<space/><link><target>Agglutination (biology)</target><part>agglutinate</part></link>. Since an antibody has at least two paratopes, it can bind more than one antigen by binding identical epitopes carried on the surfaces of these antigens. By coating the pathogen, antibodies stimulate effector functions against the pathogen in cells that recognize their Fc region.<extension extension_name='ref' name="Pier"></extension></paragraph><paragraph>Those cells that recognize coated pathogens have Fc receptors, which, as the name suggests, interact with the<space/><link><target>Fc region</target></link><space/>of IgA, IgG, and IgE antibodies. The engagement of a particular antibody with the Fc receptor on a particular cell triggers an effector function of that cell; phagocytes will<space/><link><target>phagocytosis</target><part>phagocytose</part></link>,<space/><link><target>mast cell</target><trail>s</trail></link><space/>and<space/><link><target>neutrophil</target><trail>s</trail></link><space/>will<space/><link><target>degranulation</target><part>degranulate</part></link>,<space/><link><target>natural killer cell</target><trail>s</trail></link><space/>will release<space/><link><target>cytokine</target><trail>s</trail></link><space/>and<space/><link><target>cytotoxic</target></link><space/>molecules; that will ultimately result in destruction of the invading microbe. The activation of natural killer cells by antibodies initiates a cytotoxic mechanism known as<space/><link><target>antibody-dependent cell-mediated cytotoxicity</target></link><space/>(ADCC) - this process may explain the efficacy of<space/><link><target>monoclonal antibodies</target></link><space/>used in<space/><link><target>biopharmaceutical</target><part>biological</part></link><space/>therapies against<space/><link><target>cancer</target></link>. The Fc receptors are isotype-specific, which gives greater flexibility to the immune system, invoking only the appropriate immune mechanisms for distinct pathogens.<extension extension_name='ref' name="Janeway5"></extension></paragraph><heading level='3'>Natural antibodies</heading><paragraph>Humans and higher primates also produce &quot;natural antibodies&quot; that are present in serum before viral infection. Natural antibodies have been defined as antibodies that are produced without any previous infection, vaccination, other foreign antigen exposure or<space/><link><target>passive immunization</target></link>. These antibodies can activate the classical complement pathway leading to lysis of enveloped virus particles long before the adaptive immune response is activated. Many natural antibodies are directed against the disaccharide<space/><link><target>galactose</target></link><space/>(1,3)-galactose (-Gal), which is found as a terminal sugar on<space/><link><target>glycosylated</target></link><space/>cell surface proteins, and generated in response to production of this sugar by bacteria contained in the human gut.<extension extension_name='ref'><template><target>cite web</target><arg name="author"><space/>Racaniello, Vincent</arg><arg name="url">http://www.virology.ws/2009/10/06/natural-antibody-protects-against-viral-infection/<space/></arg><arg name="date">6 October 2009<space/></arg><arg name="title">Natural antibody protects against viral infection<space/></arg><arg name="work">Virology Blog<space/></arg><arg name="accessdate">22 January 2010</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uJzysytc<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>Rejection of<space/><link><target>Organ xenotransplantation</target><part>xenotransplantated organs</part></link><space/>is thought to be, in part, the result of natural antibodies circulating in the serum of the recipient binding to -Gal antigens expressed on the donor tissue.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Milland J, Sandrin MS<space/></arg><arg name="title">ABO blood group and related antigens, natural antibodies and transplantation<space/></arg><arg name="journal">Tissue Antigens<space/></arg><arg name="volume">68<space/></arg><arg name="issue">6<space/></arg><arg name="pages">459–466<space/></arg><arg name="date">December 2006<space/></arg><arg name="pmid">17176435<space/></arg><arg name="doi">10.1111/j.1399-0039.2006.00721.x<space/></arg></template></extension></paragraph><heading level='2'>Immunoglobulin diversity</heading><paragraph>Virtually all microbes can trigger an antibody response. Successful recognition and eradication of many different types of microbes requires diversity among antibodies; their amino acid composition varies allowing them to interact with many different antigens.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Mian I, Bradwell A, Olson A<space/></arg><arg name="title">Structure, function and properties of antibody binding sites<space/></arg><arg name="journal">J Mol Biol<space/></arg><arg name="volume">217<space/></arg><arg name="issue">1<space/></arg><arg name="pages">133–151<space/></arg><arg name="year">1991<space/></arg><arg name="pmid">1988675<space/></arg><arg name="doi">10.1016/0022-2836(91)90617-F</arg></template></extension><space/>It has been estimated that humans generate about 10&amp;nbsp;billion different antibodies, each capable of binding a distinct epitope of an antigen.<extension extension_name='ref' name="pmid8612345"><template><target>cite journal</target><arg name="author">Fanning LJ, Connor AM, Wu GE<space/></arg><arg name="title">Development of the immunoglobulin repertoire<space/></arg><arg name="journal">Clin. Immunol. Immunopathol.<space/></arg><arg name="volume">79<space/></arg><arg name="issue">1<space/></arg><arg name="pages">1–14<space/></arg><arg name="year">1996<space/></arg><arg name="pmid">8612345<space/></arg><arg name="doi">10.1006/clin.1996.0044</arg></template></extension><space/>Although a huge repertoire of different antibodies is generated in a single individual, the number of<space/><link><target>gene</target><trail>s</trail></link><space/>available to make these proteins is limited by the size of the human genome. Several complex genetic mechanisms have evolved that allow vertebrate B cells to generate a diverse pool of antibodies from a relatively small number of antibody genes.<extension extension_name='ref' name="namazee"><template><target>cite journal</target><arg name="author">Nemazee D<space/></arg><arg name="title">Receptor editing in lymphocyte development and central tolerance<space/></arg><arg name="journal">Nat Rev Immunol<space/></arg><arg name="volume">6<space/></arg><arg name="issue">10<space/></arg><arg name="pages">728–740<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16998507<space/></arg><arg name="doi">10.1038/nri1939</arg></template></extension></paragraph><heading level='3'>Domain variability</heading><paragraph><link><target>File:Complementarity determining regions.PNG</target><part>thumb</part><part>250px</part><part>right</part><part>The complementarity determining regions of the heavy chain are shown in red (<template><target>PDB</target><arg>1IGT</arg></template>)</part></link>The chromosomal region that encodes an antibody is large and contains several distinct gene loci for each domain of the antibodythe chromosome region containing heavy chain genes (<link><target>IGH@</target></link>) is found on<space/><link><target>chromosome 14</target></link>, and the loci containing lambda and kappa light chain genes (<link><target>IGL@</target></link><space/>and<space/><link><target>IGK@</target></link>) are found on chromosomes<space/><link><target>chromosome 22</target><part>22</part></link><space/>and<space/><link><target>chromosome 2</target><part>2</part></link><space/>in humans. One of these domains is called the variable domain, which is present in each heavy and light chain of every antibody, but can differ in different antibodies generated from distinct B cells. Differences, between the variable domains, are located on three loops known as hypervariable regions (HV-1, HV-2 and HV-3) or<space/><link><target>complementarity determining region</target><trail>s</trail></link><space/>(CDR1, CDR2 and CDR3). CDRs are supported within the variable domains by conserved framework regions. The heavy chain locus contains about 65 different variable domain genes that all differ in their CDRs. Combining these genes with an array of genes for other domains of the antibody generates a large cavalry of antibodies with a high degree of variability. This combination is called V(D)J recombination discussed below.<extension extension_name='ref'>Peter Parham. &quot;The Immune System. 2nd ed. Garland Science: New York, 2005. pg.4762</extension></paragraph><heading level='3'>V(D)J recombination</heading><paragraph><template><target>details</target><arg>V%28D%29J recombination</arg></template><link><target>File:VDJ recombination.png</target><part>thumb</part><part>250px</part><part>right</part><part>Simplified overview of V(D)J recombination of immunoglobulin heavy chains</part></link>Somatic recombination of immunoglobulins, also known as<space/><italics>V(D)J recombination</italics>, involves the generation of a unique immunoglobulin variable region. The variable region of each immunoglobulin heavy or light chain is encoded in several piecesknown as gene segments (subgenes). These segments are called variable (V), diversity (D) and joining (J) segments.<extension extension_name='ref' name="namazee"></extension><space/>V, D and J segments are found in<space/><link><target>immunoglobulin heavy chain</target><part>Ig heavy chains</part></link>, but only V and J segments are found in<space/><link><target>Immunoglobulin light chain</target><part>Ig light chains</part></link>. Multiple copies of the V, D and J gene segments exist, and are tandemly arranged in the<space/><link><target>genome</target><trail>s</trail></link><space/>of<space/><link><target>mammal</target><trail>s</trail></link>. In the bone marrow, each developing B cell will assemble an immunoglobulin variable region by randomly selecting and combining one V, one D and one J gene segment (or one V and one J segment in the light chain). As there are multiple copies of each type of gene segment, and different combinations of gene segments can be used to generate each immunoglobulin variable region, this process generates a huge number of antibodies, each with different<space/><link><target>wikt:paratope</target><part>paratopes</part></link>, and thus different antigen specificities.<extension extension_name='ref' name="Market"></extension><space/>Interestingly, the rearrangement of several subgenes (i.e. V2 family) for lambda light chain immunoglobulin is coupled with the activation of microRNA miR-650, which further influences biology of B-cells.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Mraz<space/></arg><arg name="first1"><space/>M. 
</arg><arg name="last2"><space/>Dolezalova<space/></arg><arg name="first2"><space/>D. 
</arg><arg name="last3"><space/>Plevova<space/></arg><arg name="first3"><space/>K. 
</arg><arg name="last4"><space/>Stano Kozubik<space/></arg><arg name="first4"><space/>K. 
</arg><arg name="last5"><space/>Mayerova<space/></arg><arg name="first5"><space/>V. 
</arg><arg name="last6"><space/>Cerna<space/></arg><arg name="first6"><space/>K. 
</arg><arg name="last7"><space/>Musilova<space/></arg><arg name="first7"><space/>K. 
</arg><arg name="last8"><space/>Tichy<space/></arg><arg name="first8"><space/>B. 
</arg><arg name="last9"><space/>Pavlova<space/></arg><arg name="first9"><space/>S. 
</arg><arg name="last10"><space/>Borsky 
</arg><arg name="doi"><space/>10.1182/blood-2011-11-394874<space/></arg><arg name="first10"><space/>M. 
</arg><arg name="last11"><space/>Verner<space/></arg><arg name="first11"><space/>J. 
</arg><arg name="last12"><space/>Doubek<space/></arg><arg name="first12"><space/>M. 
</arg><arg name="last13"><space/>Brychtova<space/></arg><arg name="first13"><space/>Y. 
</arg><arg name="last14"><space/>Trbusek<space/></arg><arg name="first14"><space/>M. 
</arg><arg name="last15"><space/>Hampl<space/></arg><arg name="first15"><space/>A. 
</arg><arg name="last16"><space/>Mayer<space/></arg><arg name="first16"><space/>J. 
</arg><arg name="last17"><space/>Pospisilova<space/></arg><arg name="first17"><space/>S. 
</arg><arg name="title"><space/>MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia 
</arg><arg name="journal"><space/>Blood 
</arg><arg name="volume"><space/>119 
</arg><arg name="issue"><space/>9 
</arg><arg name="pages"><space/>2110–2113 
</arg><arg name="year"><space/>2012 
</arg><arg name="pmid"><space/>22234685 
</arg><arg name="pmc"><space/>
</arg></template></extension></paragraph><paragraph>After a B cell produces a functional immunoglobulin gene during V(D)J recombination, it cannot express any other variable region (a process known as<space/><link><target>allelic exclusion</target></link>) thus each B cell can produce antibodies containing only one kind of variable chain.<extension extension_name='ref' name="Janeway5"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Bergman Y, Cedar H<space/></arg><arg name="title">A stepwise epigenetic process controls immunoglobulin allelic exclusion<space/></arg><arg name="journal">Nat Rev Immunol<space/></arg><arg name="volume">4<space/></arg><arg name="issue">10<space/></arg><arg name="pages">753–761<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">15459667<space/></arg><arg name="doi">10.1038/nri1458</arg></template></extension></paragraph><heading level='3'>Somatic hypermutation and affinity maturation</heading><list type='ident'><listitem><italics>For more details on this topic, see<space/><link><target>Somatic hypermutation</target></link><space/>and<space/><link><target>Affinity maturation</target></link></italics></listitem></list><paragraph>Following activation with antigen, B cells begin to<space/><link><target>Cell division</target><part>proliferate</part></link><space/>rapidly. In these rapidly dividing cells, the genes encoding the variable domains of the heavy and light chains undergo a high rate of<space/><link><target>point mutation</target></link>, by a process called<space/><italics>somatic hypermutation</italics><space/>(SHM). SHM results in approximately one<space/><link><target>nucleotide</target></link><space/>change per variable gene, per cell division.<extension extension_name='ref' name="diaz"></extension><space/>As a consequence, any daughter B cells will acquire slight<space/><link><target>amino acid</target></link><space/>differences in the variable domains of their antibody chains.</paragraph><paragraph>This serves to increase the diversity of the antibody pool and impacts the antibody's antigen-binding<space/><link><target>Chemical affinity</target><part>affinity</part></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Honjo T, Habu S<space/></arg><arg name="title">Origin of immune diversity: genetic variation and selection<space/></arg><arg name="journal">Annu Rev Biochem<space/></arg><arg name="volume">54<space/></arg><arg name="issue"><space/>1</arg><arg name="pages">803–830<space/></arg><arg name="year">1985<space/></arg><arg name="pmid">3927822<space/></arg><arg name="doi">10.1146/annurev.bi.54.070185.004103</arg></template></extension><space/>Some point mutations will result in the production of antibodies that have a weaker interaction (low affinity) with their antigen than the original antibody, and some mutations will generate antibodies with a stronger interaction (high affinity).<extension extension_name='ref' name="orguil"><template><target>cite journal</target><arg name="author">Or-Guil M, Wittenbrink N, Weiser AA, Schuchhardt J<space/></arg><arg name="title">Recirculation of germinal center B cells: a multilevel selection strategy for antibody maturation<space/></arg><arg name="journal">Immunol. Rev.<space/></arg><arg name="volume">216<space/></arg><arg name="pages">130–41<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17367339<space/></arg><arg name="doi">10.1111/j.1600-065X.2007.00507.x</arg></template></extension><space/>B cells that express high affinity antibodies on their surface will receive a strong survival signal during interactions with other cells, whereas those with low affinity antibodies will not, and will die by<space/><link><target>apoptosis</target></link>.<extension extension_name='ref' name="orguil"></extension><space/>Thus, B cells expressing antibodies with a higher affinity for the antigen will outcompete those with weaker affinities for function and survival. The process of generating antibodies with increased binding affinities is called<space/><italics>affinity maturation</italics>. Affinity maturation occurs in mature B cells after V(D)J recombination, and is dependent on help from<space/><link><target>helper T cell</target><trail>s</trail></link>.<extension extension_name='ref'><template><target>Cite journal</target><arg name="author"><space/>Neuberger M, Ehrenstein M, Rada C, Sale J, Batista F, Williams G, Milstein C<space/></arg><arg name="title">Memory in the B-cell compartment: antibody affinity maturation<space/></arg><arg name="journal">Philos Trans R Soc Lond B Biol Sci<space/></arg><arg name="volume">355<space/></arg><arg name="issue">1395<space/></arg><arg name="pages">357–360<space/></arg><arg name="date">March 2000<space/></arg><arg name="pmid">10794054<space/></arg><arg name="pmc">1692737<space/></arg><arg name="doi">10.1098/rstb.2000.0573</arg></template></extension><link><target>File:Class switch recombination.png</target><part>thumb</part><part>250px</part><part>right</part><part>Mechanism of class switch recombination that allows isotype switching in activated B cells</part></link></paragraph><heading level='3'>Class switching</heading><paragraph><link><target>Immunoglobulin class switching</target><part>Isotype or class switching</part></link><space/>is a<space/><link><target>biological process</target></link><space/>occurring after activation of the B cell, which allows the cell to produce different classes of antibody (IgA, IgE, or IgG).<extension extension_name='ref' name="Market"></extension><space/>The different classes of antibody, and thus effector functions, are defined by the constant (C) regions of the immunoglobulin heavy chain. Initially, naive B cells express only cell-surface IgM and IgD with identical antigen binding regions. Each isotype is adapted for a distinct function; therefore, after activation, an antibody with an IgG, IgA, or IgE effector function might be required to effectively eliminate an antigen. Class switching allows different daughter cells from the same activated B cell to produce antibodies of different isotypes. Only the constant region of the antibody heavy chain changes during class switching; the variable regions, and therefore antigen specificity, remain unchanged. Thus the progeny of a single B cell can produce antibodies, all specific for the same antigen, but with the ability to produce the effector function appropriate for each antigenic challenge. Class switching is triggered by cytokines; the isotype generated depends on which cytokines are present in the B cell environment.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Stavnezer J, Amemiya CT<space/></arg><arg name="title">Evolution of isotype switching<space/></arg><arg name="journal">Semin. Immunol.<space/></arg><arg name="volume">16<space/></arg><arg name="issue">4<space/></arg><arg name="pages">257–275<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">15522624<space/></arg><arg name="doi">10.1016/j.smim.2004.08.005</arg></template></extension></paragraph><paragraph>Class switching occurs in the heavy chain gene<space/><link><target>Locus (genetics)</target><part>locus</part></link><space/>by a mechanism called class switch recombination (CSR). This mechanism relies on conserved<space/><link><target>nucleotide</target></link><space/>motifs, called<space/><italics>switch (S) regions</italics>, found in<space/><link><target>DNA</target></link><space/>upstream of each constant region gene (except in the -chain). The DNA strand is broken by the activity of a series of<space/><link><target>enzyme</target><trail>s</trail></link><space/>at two selected S-regions.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Durandy A<space/></arg><arg name="title">Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation<space/></arg><arg name="journal">Eur. J. Immunol.<space/></arg><arg name="volume">33<space/></arg><arg name="issue">8<space/></arg><arg name="pages">2069–2073<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">12884279<space/></arg><arg name="doi">10.1002/eji.200324133</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Casali P, Zan H<space/></arg><arg name="title">Class switching and Myc translocation: how does DNA break?<space/></arg><arg name="journal">Nat. Immunol.<space/></arg><arg name="volume">5<space/></arg><arg name="issue">11<space/></arg><arg name="pages">1101–1103<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">15496946<space/></arg><arg name="doi">10.1038/ni1104-1101</arg></template></extension><space/>The variable domain<space/><link><target>exon</target></link><space/>is rejoined through a process called<space/><link><target>non-homologous end joining</target></link><space/>(NHEJ) to the desired constant region (, or ). This process results in an immunoglobulin gene that encodes an antibody of a different isotype.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Lieber MR, Yu K, Raghavan SC<space/></arg><arg name="title">Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations<space/></arg><arg name="journal">DNA Repair (Amst.)<space/></arg><arg name="volume">5<space/></arg><arg name="issue">9–10<space/></arg><arg name="pages">1234–1245<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16793349<space/></arg><arg name="doi">10.1016/j.dnarep.2006.05.013</arg></template></extension></paragraph><heading level='3'>Affinity designations</heading><paragraph><template><target>anchor</target><arg>valence</arg></template>A group of antibodies can be called<space/><italics>monovalent</italics><space/>(or<space/><italics>specific</italics>) if they have affinity for the same epitope,<extension extension_name='ref'><link type='external' href='http://books.google.se/books?id=TfW5sUfeM5gC&amp;amp;pg=PA22'>page 22</link><space/>in:<space/><template><target>Cite book</target><arg name="last1"><space/>Shoenfeld<space/></arg><arg name="first1"><space/>Yehuda.<space/></arg><arg name="last2"><space/>Meroni<space/></arg><arg name="first2"><space/>Pier-Luigi.<space/></arg><arg name="last3"><space/>Gershwin<space/></arg><arg name="first3"><space/>M. Eric<space/></arg><arg name="title"><space/>Autoantibodie<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="publisher"><space/>Elsevier<space/></arg><arg name="location"><space/>Amsterdam; Boston<space/></arg><arg name="isbn"><space/>978-0-444-52763-9<space/></arg><arg name="pages"></arg></template></extension><space/>or for the same antigen<extension extension_name='ref' name="farlex-monovalent"><link type='external' href='http://www.thefreedictionary.com/monovalent'>Farlex dictionary: monovalent</link><space/>Citing: The American Heritage Science Dictionary, Copyright 2005</extension><space/>(but potentially different epitopes on the molecule), or for the same strain of microorganism<extension extension_name='ref' name="farlex-monovalent"></extension><space/>(but potentially different antigens on or in it). In contrast, a group of antibodies can be called<space/><italics>polyvalent</italics><space/>(or<space/><italics>unspecific</italics>) if they have affinity for various antigens<extension extension_name='ref' name="farlex-polyvalent"></extension><space/>or microorganisms.<extension extension_name='ref' name="farlex-polyvalent"><link type='external' href='http://medical-dictionary.thefreedictionary.com/polyvalent'>Farlex dictionary &gt; polyvalent</link><space/>Citing: The American Heritage Medical Dictionary. 2004</extension><space/><link><target>Intravenous immunoglobulin</target></link>, if not otherwise noted, consists of polyvalent IgG. In contrast,<space/><link><target>monoclonal antibodies</target></link><space/>are monovalent for the same epitope.</paragraph><heading level='3'>Asymmetrical antibodies</heading><paragraph>Heterodimeric antibodies, which are also asymmetrical and antibodies, allow for greater flexibility and new formats for attaching a variety of drugs to the antibody arms. One of the general formats for a heterodimeric antibody is the knobs-into-holes format. This format is specific to the heavy chain part of the constant region in antibodies. The knobs part is engineered by replacing a small amino acid with a larger one. It fits into the hole, which is engineered by replacing a large amino acid with a smaller one. What connects the knobs to the holes are the disulfide bonds between each chain. The knobs-into-holes shape facilitates antibody dependent cell mediated cytotoxicity. Single chain variable fragments (scFv) are connected to the variable domain of the heavy and light chain via a short linker peptide. The linker is rich in glycine, which gives it more flexibility, and serine/threonine, which gives it specificity. Two different scFv fragments can be connected together, via a hinge region, to the constant domain of the heavy chain or the constant domain of the light chain.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Gunasekaran L<space/></arg><arg name="title">Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG<space/></arg><arg name="journal">The Journal of Biological Chemistry<space/></arg><arg name="volume">285<space/></arg><arg name="issue">25<space/></arg><arg name="pages">19637–19646<space/></arg><arg name="year">2010<space/></arg><arg name="doi">10.1016/S0014-5793(98)00021-0</arg></template></extension><space/>This gives the antibody bispecificity, allowing for the binding specificities of two different antigens.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Muller K.M<space/></arg><arg name="title">The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies<space/></arg><arg name="journal">FEBS Letters<space/></arg><arg name="volume">422<space/></arg><arg name="issue">2<space/></arg><arg name="pages">259–264<space/></arg><arg name="year">1998<space/></arg><arg name="doi">10.1074/jbc.M110.117382</arg></template></extension><space/>The knobs-into-holes format enhances heterodimer formation but doesnt suppress homodimer formation.</paragraph><paragraph>To further improve the function of heterodimeric antibodies, many scientists are looking towards artificial constructs. Artificial antibodies are largely diverse protein motifs that use the functional strategy of the antibody molecule, but arent limited by the loop and framework structural constraints of the natural antibody.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Gao C<space/></arg><arg name="title">Making artificial antibodies: A format for phage display of combinatorial heterodimeric arrays<space/></arg><arg name="journal">PNAS<space/></arg><arg name="volume">96<space/></arg><arg name="issue">11<space/></arg><arg name="pages">6025–6030<space/></arg><arg name="year">1999<space/></arg><arg name="doi">10.1073/pnas.96.11.6025<space/></arg><arg name="pmid">10339535<space/></arg><arg name="pmc">26829</arg></template></extension><space/>Being able to control the combinational design of the sequence and three-dimensional space could transcend the natural design and allow for the attachment of different combinations of drugs to the arms.</paragraph><paragraph>Heterodimeric antibodies have a greater range in shapes they can take and the drugs that are attached to the arms dont have to be the same on each arm, allowing for different combinations of drugs to be used in cancer treatment. Pharmaceuticals are able to produce highly functional bispecific, and even multispecific, antibodies. The degree to which they can function is impressive given that such a change shape from the natural form should lead to decreased functionality.</paragraph><heading level='2'>Medical applications</heading><heading level='3'>Disease diagnosis and therapy</heading><paragraph>Detection of particular antibodies is a very common form of medical<space/><link><target>medical diagnosis</target><part>diagnostics</part></link>, and applications such as<space/><link><target>serology</target></link><space/>depend on these methods.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.immunospot.eu/elisa-animation.html<space/></arg><arg name="title">Animated depictions of how antibodies are used in ELISA assays<space/></arg><arg name="accessdate">8 May 2007<space/></arg><arg name="work">Cellular Technology Ltd.—Europe</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK00Qems<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>For example, in biochemical assays for disease diagnosis,<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.immunospot.eu/elispot-animation.html<space/></arg><arg name="title">Animated depictions of how antibodies are used in ELISPOT assays<space/></arg><arg name="accessdate">8 May 2007<space/></arg><arg name="work">Cellular Technology Ltd.—Europe</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK00pHh5<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>a<space/><link><target>titer</target></link><space/>of antibodies directed against<space/><link><target>Epstein-Barr virus</target></link><space/>or<space/><link><target>Lyme disease</target></link><space/>is estimated from the blood. If those antibodies are not present, either the person is not infected or the infection occurred a<space/><italics>very</italics><space/>long time ago, and the B cells generating these specific antibodies have naturally decayed.</paragraph><paragraph>In<space/><link><target>clinical immunology</target></link>, levels of individual classes of immunoglobulins are measured by<space/><link><target>nephelometry</target></link><space/>(or turbidimetry) to characterize the antibody profile of patient.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Stern P<space/></arg><arg name="title">Current possibilities of turbidimetry and nephelometry<space/></arg><arg name="journal">Klin Biochem Metab<space/></arg><arg name="volume">14<space/></arg><arg name="issue">3<space/></arg><arg name="pages">146–151<space/></arg><arg name="year">2006</arg><arg name="url"><space/>http://www.clsjep.cz/odkazy/kbm0603-146.pdf</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK01zkxp<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>Elevations in different classes of immunoglobulins are sometimes useful in determining the cause of<space/><link><target>liver</target></link><space/>damage in patients for whom the diagnosis is unclear.<extension extension_name='ref' name="Rhoades"></extension><space/>For example, elevated IgA indicates alcoholic<space/><link><target>cirrhosis</target></link>, elevated IgM indicates<space/><link><target>viral hepatitis</target></link><space/>and<space/><link><target>primary biliary cirrhosis</target></link>, while IgG is elevated in viral hepatitis,<space/><link><target>autoimmune hepatitis</target></link><space/>and cirrhosis.<space/></paragraph><paragraph><link><target>Autoimmune disorder</target><trail>s</trail></link><space/>can often be traced to antibodies that bind the body's own<space/><link><target>epitope</target><trail>s</trail></link>; many can be detected through<space/><link><target>blood test</target><trail>s</trail></link>. Antibodies directed against<space/><link><target>red blood cell</target></link><space/>surface antigens in immune mediated<space/><link><target>hemolytic anemia</target></link><space/>are detected with the<space/><link><target>Coombs test</target></link>.<extension extension_name='ref' name="Dean"><template><target>cite book</target><arg name="last">Dean<space/></arg><arg name="first">Laura<space/></arg><arg name="title"><space/>Blood Groups and Red Cell Antigens</arg><arg name="year"><space/>2005</arg><arg name="publisher">National Library of Medicine (US),<space/></arg><arg name="location">NCBI Bethesda (MD)</arg><arg name="chapter"><space/>Chapter 4: Hemolytic disease of the newborn<space/></arg><arg name="chapterurl"><space/>http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid</arg></template></extension><space/>The Coombs test is also used for antibody screening in<space/><link><target>blood transfusion</target></link><space/>preparation and also for antibody screening in<space/><link><target>antenatal</target></link><space/>women.<extension extension_name='ref' name="Dean"></extension></paragraph><paragraph>Practically, several immunodiagnostic methods based on detection of complex antigen-antibody are used to diagnose infectious diseases, for example<space/><link><target>ELISA</target></link>,<space/><link><target>immunofluorescence</target></link>,<space/><link><target>Western blot</target></link>,<space/><link><target>immunodiffusion</target></link>,<space/><link><target>immunoelectrophoresis</target></link>, and<space/><link><target>magnetic immunoassay</target></link>. Antibodies raised against human chorionic gonadotropin are used in over the counter pregnancy tests.</paragraph><paragraph>Targeted<space/><link><target>monoclonal antibody therapy</target></link><space/>is employed to treat diseases such as<space/><link><target>rheumatoid arthritis</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Feldmann M, Maini R<space/></arg><arg name="title">Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?<space/></arg><arg name="journal">Annu Rev Immunol<space/></arg><arg name="volume">19<space/></arg><arg name="issue"><space/>1</arg><arg name="pages">163–196<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11244034<space/></arg><arg name="doi">10.1146/annurev.immunol.19.1.163</arg></template></extension><space/><link><target>multiple sclerosis</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Doggrell S<space/></arg><arg name="title">Is natalizumab a breakthrough in the treatment of multiple sclerosis?<space/></arg><arg name="journal">Expert Opin Pharmacother<space/></arg><arg name="volume">4<space/></arg><arg name="issue">6<space/></arg><arg name="pages">999–1001<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">12783595<space/></arg><arg name="doi">10.1517/14656566.4.6.999</arg></template></extension><space/><link><target>psoriasis</target></link>,<extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Krueger G, Langley R, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley L, Lebwohl M<space/></arg><arg name="title">A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis</arg><arg name="journal"><space/>[[N Engl J Med]]</arg><arg name="volume">356<space/></arg><arg name="issue">6<space/></arg><arg name="pages">580–592<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17287478<space/></arg><arg name="doi">10.1056/NEJMoa062382</arg></template></extension><space/>and many forms of<space/><link><target>cancer</target></link><space/>including<space/><link><target>non-Hodgkin's lymphoma</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Plosker G, Figgitt D<space/></arg><arg name="title">Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia<space/></arg><arg name="journal">Drugs<space/></arg><arg name="volume">63<space/></arg><arg name="issue">8<space/></arg><arg name="pages">803–843<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">12662126<space/></arg><arg name="doi">10.2165/00003495-200363080-00005</arg></template></extension><space/><link><target>colorectal cancer</target></link>,<space/><link><target>head and neck cancer</target></link><space/>and<space/><link><target>breast cancer</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L, Slamon D, Murphy M, Novotny W, Burchmore M, Shak S, Stewart S<space/></arg><arg name="title">First-line Herceptin monotherapy in metastatic breast cancer<space/></arg><arg name="series">61<space/></arg><arg name="journal">Oncology<space/></arg><arg name="volume">Suppl 2<space/></arg><arg name="issue"><space/>Suppl. 2</arg><arg name="pages">37–42<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11694786<space/></arg><arg name="doi">10.1159/000055400</arg></template></extension></paragraph><paragraph>Some immune deficiencies, such as<space/><link><target>X-linked agammaglobulinemia</target></link><space/>and<space/><link><target>hypogammaglobulinemia</target></link>, result in partial or complete lack of antibodies.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>LeBien TW<space/></arg><arg name="title"><space/>Fates of human B-cell precursors<space/></arg><arg name="journal"><space/>Blood<space/></arg><arg name="volume"><space/>96<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>9–23<space/></arg><arg name="date">1 July 2000</arg><arg name="pmid"><space/>10891425<space/></arg><arg name="url"><space/>http://bloodjournal.hematologylibrary.org/cgi/content/full/96/1/9<space/></arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK02zfmd<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>These diseases are often treated by inducing a short term form of<space/><link><target>immunity (medical)</target><part>immunity</part></link><space/>called<space/><link><target>passive immunity</target></link>. Passive immunity is achieved through the transfer of ready-made antibodies in the form of human or animal<space/><link><target>blood plasma</target><part>serum</part></link>, pooled immunoglobulin or monoclonal antibodies, into the affected individual.<extension extension_name='ref' name="USC"><template><target>cite web</target><arg name="author"><space/>Ghaffer A<space/></arg><arg name="title"><space/>Immunization<space/></arg><arg name="work"><space/>Immunology&nbsp;— Chapter 14<space/></arg><arg name="publisher"><space/>University of South Carolina School of Medicine<space/></arg><arg name="url"><space/>http://pathmicro.med.sc.edu/ghaffar/immunization.htm<space/></arg><arg name="date"><space/>26 March 2006<space/></arg><arg name="accessdate"><space/>6 June 2007</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK03Lul6<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension></paragraph><heading level='3'>Prenatal therapy</heading><paragraph><link><target>Rhesus factor</target></link>, also known as Rhesus D (RhD) antigen, is an antigen found on<space/><link><target>red blood cell</target><trail>s</trail></link>; individuals that are Rhesus-positive (Rh+) have this antigen on their red blood cells and individuals that are Rhesus-negative (Rh) do not. During normal<space/><link><target>childbirth</target></link>, delivery trauma or complications during pregnancy, blood from a<space/><link><target>fetus</target></link><space/>can enter the mother's system. In the case of an Rh-incompatible mother and child, consequential blood mixing may sensitize an Rh- mother to the Rh antigen on the blood cells of the Rh+ child, putting the remainder of the<space/><link><target>pregnancy</target></link>, and any subsequent pregnancies, at risk for<space/><link><target>hemolytic disease of the newborn</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Urbaniak S, Greiss M<space/></arg><arg name="title">RhD haemolytic disease of the fetus and the newborn<space/></arg><arg name="journal">Blood Rev<space/></arg><arg name="volume">14<space/></arg><arg name="issue">1<space/></arg><arg name="pages">44–61<space/></arg><arg name="year">2000<space/></arg><arg name="pmid">10805260<space/></arg><arg name="doi">10.1054/blre.1999.0123</arg></template></extension></paragraph><paragraph><link><target>Rho(D) immune globulin</target></link><space/>antibodies are specific for human Rhesus D (RhD) antigen.<extension extension_name='ref' name="Fung"><template><target>cite journal</target><arg name="author1">Fung Kee Fung K<space/></arg><arg name="author2">Eason E<space/></arg><arg name="author3">Crane J<space/></arg><arg name="author4">Armson A<space/></arg><arg name="author5">De La Ronde S<space/></arg><arg name="author6">Farine D<space/></arg><arg name="author7">Keenan-Lindsay L<space/></arg><arg name="author8">Leduc L<space/></arg><arg name="author9">Reid GJ<space/></arg><arg name="author10">Aerde JV<space/></arg><arg name="author11">Wilson RD<space/></arg><arg name="author12">Davies G<space/></arg><arg name="author13">Désilets VA<space/></arg><arg name="author14">Summers A<space/></arg><arg name="author15">Wyatt P<space/></arg><arg name="author16">Young DC<space/></arg><arg name="author17">Maternal-Fetal Medicine Committee<space/></arg><arg name="author18">Genetics Committee<space/></arg><arg name="title">Prevention of Rh alloimmunization<space/></arg><arg name="journal">J Obstet Gynaecol Can<space/></arg><arg name="volume">25<space/></arg><arg name="issue">9<space/></arg><arg name="pages">765–73<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">12970812</arg></template></extension><space/>Anti-RhD antibodies are administered as part of a<space/><link><target>prenatal care</target><part>prenatal treatment regimen</part></link><space/>to prevent sensitization that may occur when a Rhesus-negative mother has a Rhesus-positive fetus. Treatment of a mother with Anti-RhD antibodies prior to and immediately after trauma and delivery destroys Rh antigen in the mother's system from the fetus. It is important to note that this occurs before the antigen can stimulate maternal B cells to &quot;remember&quot; Rh antigen by generating memory B cells. Therefore, her humoral immune system will not make anti-Rh antibodies, and will not attack the Rhesus antigens of the current or subsequent babies. Rho(D) Immune Globulin treatment prevents sensitization that can lead to<space/><link><target>Rh disease</target></link>, but does not prevent or treat the underlying disease itself.<extension extension_name='ref' name="Fung"></extension></paragraph><heading level='2'>Research applications</heading><paragraph><link><target>File:FluorescentCells.jpg</target><part>thumb</part><part>right</part><part>200px</part><part><link><target>Immunofluorescence</target></link><space/>image of the eukaryotic<space/><link><target>cytoskeleton</target></link>.<space/><link><target>Actin</target></link><space/>filaments are shown in red,<space/><link><target>microtubule</target><trail>s</trail></link><space/>in green, and the<space/><link><target>cell nucleus</target><part>nuclei</part></link><space/>in blue.</part></link></paragraph><paragraph>Specific antibodies are produced by injecting an<space/><link><target>antigen</target></link><space/>into a<space/><link><target>mammal</target></link>, such as a<space/><link><target>mouse</target></link>,<space/><link><target>rat</target></link>,<space/><link><target>rabbit</target></link>,<space/><link><target>goat</target></link>,<space/><link><target>sheep</target></link>, or<space/><link><target>horse</target></link><space/>for large quantities of antibody. Blood isolated from these animals contains<space/><italics><link><target>polyclonal antibodies</target></link></italics>multiple antibodies that bind to the same antigenin the<space/><link><target>Blood plasma</target><part>serum</part></link>, which can now be called<space/><link><target>antiserum</target></link>. Antigens are also injected into<space/><link><target>chicken</target><trail>s</trail></link><space/>for generation of polyclonal antibodies in<space/><link><target>egg yolk</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Tini M, Jewell UR, Camenisch G, Chilov D, Gassmann M<space/></arg><arg name="title">Generation and application of chicken egg-yolk antibodies<space/></arg><arg name="journal">Comp. Biochem. Physiol., Part a Mol. Integr. Physiol.<space/></arg><arg name="volume">131<space/></arg><arg name="issue">3<space/></arg><arg name="pages">569–574<space/></arg><arg name="year">2002<space/></arg><arg name="pmid">11867282<space/></arg><arg name="doi">10.1016/S1095-6433(01)00508-6</arg></template></extension><space/>To obtain antibody that is specific for a single epitope of an antigen, antibody-secreting<space/><link><target>lymphocyte</target><trail>s</trail></link><space/>are isolated from the animal and<space/><link><target>Biological immortality</target><part>immortalized</part></link><space/>by fusing them with a cancer cell line. The fused cells are called<space/><link><target>hybridoma</target><trail>s</trail></link>, and will continually grow and secrete antibody in culture. Single hybridoma cells are isolated by<space/><link><target>dilution cloning</target></link><space/>to generate<space/><link><target>cloning#Cellular cloning</target><part>cell clones</part></link><space/>that all produce the same antibody; these antibodies are called<space/><italics><link><target>monoclonal antibodies</target></link></italics>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Cole SP, Campling BG, Atlaw T, Kozbor D, Roder JC<space/></arg><arg name="title">Human monoclonal antibodies<space/></arg><arg name="journal">Mol. Cell. Biochem.<space/></arg><arg name="volume">62<space/></arg><arg name="issue">2<space/></arg><arg name="pages">109–20<space/></arg><arg name="year">1984<space/></arg><arg name="pmid">6087121<space/></arg><arg name="doi">10.1007/BF00223301</arg></template></extension><space/>Polyclonal and monoclonal antibodies are often purified using<space/><link><target>Protein A/G</target></link><space/>or<space/><link><target>Affinity chromatography</target><part>antigen-affinity chromatography</part></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Kabir S<space/></arg><arg name="title">Immunoglobulin purification by affinity chromatography using protein A mimetic ligands prepared by combinatorial chemical synthesis<space/></arg><arg name="journal">Immunol Invest<space/></arg><arg name="volume">31<space/></arg><arg name="issue">3–4<space/></arg><arg name="pages">263–278<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid">12472184<space/></arg><arg name="doi">10.1081/IMM-120016245</arg></template></extension></paragraph><paragraph>In research, purified antibodies are used in many applications. Antibodies for research applications can be found directly from antibody suppliers, or through use of a specialist search engine. Research antibodies are most commonly used to identify and locate<space/><link><target>intracellular</target></link><space/>and<space/><link><target>extracellular</target></link><space/>proteins. Antibodies are used in<space/><link><target>flow cytometry</target></link><space/>to differentiate cell types by the proteins they express; different types of cell express different combinations of<space/><link><target>cluster of differentiation</target></link><space/>molecules on their surface, and produce different intracellular and secretable proteins.<extension extension_name='ref' name="Stecher"><template><target>cite journal</target><arg name="author">Brehm-Stecher B, Johnson E<space/></arg><arg name="title">Single-cell microbiology: tools, technologies, and applications<space/></arg><arg name="url">http://mmbr.asm.org/cgi/content/full/68/3/538?view</arg><arg name="doi"><space/>10.1128/MMBR.68.3.538-559.2004<space/></arg><arg name="journal">Microbiol Mol Biol Rev<space/></arg><arg name="volume">68<space/></arg><arg name="issue">3<space/></arg><arg name="pages">538–559<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">15353569<space/></arg><arg name="pmc">515252</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK04DmZC<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>They are also used in<space/><link><target>immunoprecipitation</target></link><space/>to separate proteins and anything bound to them (co-immunoprecipitation) from other molecules in a<space/><link><target>cell lysate</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Williams N<space/></arg><arg name="title">Immunoprecipitation procedures<space/></arg><arg name="journal">Methods Cell Biol<space/></arg><arg name="volume">62</arg><arg name="pages">449–453<space/></arg><arg name="year">2000<space/></arg><arg name="pmid">10503210<space/></arg><arg name="doi">10.1016/S0091-679X(08)61549-6<space/></arg><arg name="series">Methods in Cell Biology<space/></arg><arg name="isbn">978-0-12-544164-3</arg></template></extension><space/>in<space/><link><target>Western blot</target></link><space/>analyses to identify proteins separated by<space/><link><target>electrophoresis</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Kurien B, Scofield R<space/></arg><arg name="title">Western blotting<space/></arg><arg name="journal">Methods<space/></arg><arg name="volume">38<space/></arg><arg name="issue">4<space/></arg><arg name="pages">283–293<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16483794<space/></arg><arg name="doi">10.1016/j.ymeth.2005.11.007</arg></template></extension><space/>and in<space/><link><target>immunohistochemistry</target></link><space/>or<space/><link><target>immunofluorescence</target></link><space/>to examine protein expression in tissue sections or to locate proteins within cells with the assistance of a<space/><link><target>microscope</target></link>.<extension extension_name='ref' name="Stecher"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Scanziani E<space/></arg><arg name="title">Immunohistochemical staining of fixed tissues<space/></arg><arg name="journal">Methods Mol Biol<space/></arg><arg name="volume">104<space/></arg><arg name="pages">133–140<space/></arg><arg name="year"><space/>1998</arg><arg name="pmid">9711649<space/></arg><arg name="doi">10.1385/0-89603-525-5:133<space/></arg><arg name="isbn">978-0-89603-525-6</arg></template></extension><space/>Proteins can also be detected and quantified with antibodies, using<space/><link><target>ELISA</target></link><space/>and<space/><link><target>ELISPOT</target></link><space/>techniques.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Reen DJ.</arg><arg name="title">Enzyme-linked immunosorbent assay (ELISA)</arg><arg name="journal">Methods Mol Biol.</arg><arg name="volume">32<space/></arg><arg name="pages">461–466<space/></arg><arg name="year"><space/>1994</arg><arg name="pmid">7951745<space/></arg><arg name="doi">10.1385/0-89603-268-X:461<space/></arg><arg name="isbn">0-89603-268-X</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Kalyuzhny AE<space/></arg><arg name="title">Chemistry and biology of the ELISPOT assay</arg><arg name="journal">Methods Mol Biol.</arg><arg name="volume">302</arg><arg name="pages">015–032<space/></arg><arg name="year"><space/>2005</arg><arg name="pmid">15937343<space/></arg><arg name="doi">10.1385/1-59259-903-6:015<space/></arg><arg name="isbn">1-59259-903-6</arg></template></extension></paragraph><paragraph>Researchers using antibodies in their work need to record them correctly in order to allow their research to be reproducible (and therefore tested, and qualified by other researchers). Less than half of research antibodies referenced in academic papers can be easily identified.<extension extension_name='ref'><template><target>cite web</target><arg name="title">On the reproducibility of science: unique identification of research resources in the biomedical literature</arg><arg name="url">https://peerj.com/articles/148/</arg><arg name="work">PeerJ</arg><arg name="accessdate">1 September 2014</arg><arg name="date">2 September 2013</arg></template></extension><space/>A paper published in<space/><link><target>F1000</target></link><space/>in 2014 provided researchers with a guide for reporting research antibody use.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Reporting research antibody use: how to increase experimental reproducibility</arg><arg name="url">http://f1000research.com/articles/2-153/v2</arg><arg name="work">F1000</arg><arg name="accessdate">1 September 2014</arg><arg name="date">23 August 2013</arg></template></extension></paragraph><heading level='2'>Regulatory validation of<space/><link><target>monoclonal antibody</target></link><space/>products for<space/><link><target>human</target></link><space/>use</heading><paragraph><bold>Production and testing :<xhtml:br></xhtml:br></bold></paragraph><paragraph>Traditionally, most antibodies are produced by hybridoma<space/><link><target>cell (biology)</target><part>cell</part></link><space/>lines through immortalization of antibody-producing cells by chemically-induced fusion with myeloma cells. In some cases, additional fusions with other lines have created &quot;triomas&quot; and &quot;quadromas&quot;. The manufacturing process should be appropriately described and validated. Validation studies shouldat least include :<xhtml:br></xhtml:br></paragraph><list type='bullet'><listitem>The demonstration that the process is able to produce in good quality (the process should be validated)</listitem><listitem></listitem><listitem>The<space/><link><target>efficiency</target></link><space/>of the antibody purification (all<space/><link><target>impurities</target></link><space/>and<space/><link><target>virus</target></link><space/>must be eliminated)</listitem><listitem></listitem><listitem>The characterization of purified antibody (<link><target>physical chemistry</target><part>physicochemical</part></link><space/>characterization,<space/><link><target>immunological</target></link><space/>properties,<space/><link><target>biological</target></link><space/>activities, contaminants, ...)</listitem><listitem>Determination of the virus clearance studies</listitem></list><paragraph><bold>Before<space/><link><target>clinical trials</target></link>, studies of product safety and feasibility have to be performed :</bold></paragraph><preblock><preline></preline></preblock><list type='bullet'><listitem>Product safety testing : Sterility (bacteria and fungi), In vitro and in vivo testing for adventitious viruses, Murine retrovirus testing... Product safety data needed before the initiation of feasibility trials in serious or immediately life-threatening conditions, it serves to evaluate dangerous potential of the product.</listitem><listitem>Feasibility testing : These are pilot studies whose objectives include, among others, early characterization of safety and initial proof of concept in a small specific patient population (in vito or in vivo testing).</listitem></list><paragraph><bold>Preclinical studies :<space/><xhtml:br></xhtml:br></bold><link><target>File:Example of tissue cross-reactivity on human tissue microarray.jpeg</target><part>thumbnail</part><part>Example of tissue cross-reactivity on human<space/><link><target>tissue microarray</target></link></part></link></paragraph><list type='bullet'><listitem>Testing<space/><link><target>cross-reactivity</target></link><space/>of antibody : to highlight unwanted interactions (toxicity) of antibodies with previously characterized tissues. This study can be performed in vitro (Reactivity of the antibody or immunoconjugate should be determined with a quick-frozen adult tissues) or in vivo (with appropriates animal models).<space/><link type='external' href='http://www.histalim.com/accueil/activities/our-expert-services/?lang=en'>More informations about in vitro cross-reactivity testing.</link></listitem><listitem>Preclinical<space/><link><target>pharmacology</target></link><space/>and<space/><link><target>toxicity</target></link><space/>testing :<space/><link><target>Preclinical</target></link><space/>safety testing of antibody is designed to identify possible toxicities in humans, to estimate the likelihood and severity of potential adverse events in humans, and to identify a safe starting dose and dose escalation, when possible.<space/></listitem><listitem>Animal toxicity studies : Acute toxicity testing, Repeat-dose toxicity testing, Long-term toxicity testing http://www.animalresearch.info/en/drug-development/safety-testing/</listitem><listitem>Pharmacokinetics and pharmacodynamics testing : Use for determinate clinical dosages, antibody activities (AUC, pharmacodynamics, biodistribution, ...), evaluation of the potential clinical effects</listitem></list><heading level='2'>Structure prediction</heading><paragraph>The importance of antibodies in health care and the<space/><link><target>biotechnology</target></link><space/>industry demands knowledge of their structures at<space/><link><target>Image resolution</target><part>high resolution</part></link>. This information is used for<space/><link><target>protein engineering</target></link>, modifying the antigen binding affinity, and identifying an epitope, of a given antibody.<space/><link><target>X-ray crystallography</target></link><space/>is one commonly used method for determining antibody structures. However, crystallizing an antibody is often laborious and time-consuming. Computational approaches provide a cheaper and faster alternative to crystallography, but their results are more equivocal, since they do not produce empirical structures. Online web servers such as<space/><italics>Web Antibody Modeling</italics><space/>(WAM)<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Whitelegg N.R.J., Rees A.R.<space/></arg><arg name="title">WAM: an improved algorithm for modeling antibodies on the WEB<space/></arg><arg name="journal">Protein Engineering</arg><arg name="volume">13</arg><arg name="issue">12<space/></arg><arg name="pages">819–824</arg><arg name="year">2000<space/></arg><arg name="doi">10.1093/protein/13.12.819<space/></arg><arg name="pmid">11239080<space/></arg><arg name="url">http://peds.oxfordjournals.org/cgi/content/abstract/13/12/819</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK04d3mA<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template><xhtml:br></xhtml:br><space/><link type='external' href='http://antibody.bath.ac.uk/abmod.html'>WAM</link></extension><space/>and<space/><italics>Prediction of Immunoglobulin Structure</italics><space/>(PIGS)<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Marcatili P, Rosi A,Tramontano A<space/></arg><arg name="title">PIGS: automatic prediction of antibody structures</arg><arg name="journal">Bioinformatics<space/></arg><arg name="volume">24</arg><arg name="issue">17<space/></arg><arg name="pages">1953–1954<space/></arg><arg name="year">2008<space/></arg><arg name="doi">10.1093/bioinformatics/btn341<space/></arg><arg name="pmid">18641403</arg><arg name="url">http://arianna.bio.uniroma1.it/pigs/</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK06XmYO<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template><xhtml:br></xhtml:br><space/><link type='external' href='http://arianna.bio.uniroma1.it/pigs/'>Prediction of Immunoglobulin Structure (PIGS)</link></extension><space/>enables computational modeling of antibody variable regions. Rosetta Antibody is a novel antibody F<xhtml:sub>V</xhtml:sub><space/>region structure prediction<space/><link><target>Server (computing)</target><part>server</part></link>, which incorporates sophisticated techniques to minimize CDR loops and optimize the relative orientation of the light and heavy chains, as well as<space/><link><target>homology (biology)</target><part>homology</part></link><space/>models that predict successful docking of antibodies with their unique antigen.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Sivasubramanian A, Sircar A, Chaudhury S, Gray J J<space/></arg><arg name="title">Toward high-resolution homology modeling of antibody Fv regions and application to antibody–antigen docking</arg><arg name="journal">Proteins<space/></arg><arg name="volume">74<space/></arg><arg name="pages">497–514<space/></arg><arg name="year">2009<space/></arg><arg name="doi">10.1002/prot.22309<space/></arg><arg name="pmc">2909601<space/></arg><arg name="pmid">19062174<space/></arg><arg name="issue">2<space/></arg><arg name="url">http://arianna.bio.uniroma1.it/pigs/</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK07ARPr</arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template><xhtml:br></xhtml:br><link type='external' href='http://antibody.graylab.jhu.edu'>RosettaAntibody</link></extension></paragraph><paragraph>The ability to describe the antibody through binding affinity to the antigen is supplemented by information on antibody structure and amino acid sequences for the purpose of patent claims.<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott</arg><arg name="last"><space/>Park<space/></arg><arg name="first"><space/>Hyeongsu<space/></arg><arg name="url"><space/>http://jolt.law.harvard.edu/digest/patent/written-description-problems-of-the-monoclonal-antibody-patents-after-centocor-v-abbott</arg><arg name="website"><space/>jolt.law.harvard.edu</arg><arg name="accessdate"><space/>12 Dec 2014</arg></template></extension></paragraph><heading level='2'>History</heading><paragraph><template><target>see also</target><arg>History of immunology</arg></template></paragraph><paragraph>The first use of the term &quot;antibody&quot; occurred in a text by<space/><link><target>Paul Ehrlich</target></link>. The term<space/><italics>Antikrper</italics><space/>(the German word for<space/><italics>antibody</italics>) appears in the conclusion of his article &quot;Experimental Studies on Immunity&quot;, published in October 1891, which states that, &quot;if two substances give rise to two different antikrper, then they themselves must be different&quot;.<extension extension_name='ref' name="Lindenmann"><template><target>cite journal</target><arg name="url">http://www3.interscience.wiley.com/cgi-bin/fulltext/119531625/PDFSTART<space/></arg><arg name="author">Lindenmann, Jean<space/></arg><arg name="title">Origin of the Terms 'Antibody' and 'Antigen'<space/></arg><arg name="journal">Scand. J. Immunol.</arg><arg name="volume">19<space/></arg><arg name="pages">281–5<space/></arg><arg name="year">1984<space/></arg><arg name="pmid">6374880<space/></arg><arg name="issue">4<space/></arg><arg name="archiveurl">http://www.webcitation.org/5uK08DeWS<space/></arg><arg name="archivedate">17 November 2010<space/></arg><arg name="deadurl">yes<space/></arg><arg name="doi">10.1111/j.1365-3083.1984.tb00931.x</arg></template></extension><space/>However, the term was not accepted immediately and several other terms for antibody were proposed; these included<space/><italics>Immunkrper</italics>,<space/><italics>Amboceptor</italics>,<space/><italics>Zwischenkrper</italics>,<space/><italics>substance sensibilisatrice</italics>,<space/><italics>copula</italics>,<space/><italics>Desmon</italics>,<space/><italics>philocytase</italics>,<space/><italics>fixateur</italics>, and<space/><italics>Immunisin</italics>.<extension extension_name='ref' name="Lindenmann"></extension><space/>The word<space/><italics>antibody</italics><space/>has formal analogy to the word<space/><italics><link><target>antitoxin</target></link></italics><space/>and a similar concept to<space/><italics>Immunkrper</italics><space/>(<italics>immune body</italics><space/>in English).<extension extension_name='ref' name="Lindenmann"></extension><space/>As such, the original construction of the word contains a logical flaw; the antitoxin is something directed against a toxin, while the antibody is a body directed against something.<extension extension_name='ref' name="Lindenmann"></extension></paragraph><paragraph><link><target>File:AngeloftheWest.jpg</target><part>thumb</part><part>left</part><part>250px</part><part>''<link><target>Angel of the West</target></link>'' (2008) by<space/><link><target>Julian Voss-Andreae</target></link><space/>is a sculpture based on the antibody structure published by E. Padlan.<extension extension_name='ref'><template><target>cite journal</target><arg name="first">Eduardo<space/></arg><arg name="last">Padlan<space/></arg><arg name="date">February 1994<space/></arg><arg name="title">Anatomy of the antibody molecule<space/></arg><arg name="journal">Mol. Immunol.<space/></arg><arg name="pmid">8114766<space/></arg><arg name="volume">31<space/></arg><arg name="issue">3<space/></arg><arg name="pages">169–217<space/></arg><arg name="doi">10.1016/0161-5890(94)90001-9</arg></template></extension><space/>Created for the Florida campus of<space/><link><target>the Scripps Research Institute</target></link>,<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>New Sculpture Portraying Human Antibody as Protective Angel Installed on Scripps Florida Campus<space/></arg><arg name="url"><space/>http://www.scripps.edu/newsandviews/e_20081110/sculpture.html<space/></arg><arg name="accessdate"><space/>12 December 2008</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK08UfTv<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>the antibody is placed into a ring referencing<space/><link><target>Leonardo da Vinci</target><part>Leonardo da Vinci's</part></link><space/>''<link><target>Vitruvian Man</target></link>'' thus highlighting the similarity of the antibody and the human body.<extension extension_name='ref'><template><target>cite web</target><arg name="last">Pescovitz<space/></arg><arg name="first">David<space/></arg><arg name="title">Protein sculpture inspired by Vitruvian Man<space/></arg><arg name="url">http://www.boingboing.net/2008/10/22/protein-sculpture-in.html<space/></arg><arg name="accessdate">12 December 2008<space/></arg><arg name="archiveurl">http://www.webcitation.org/5uK0Ai3D4<space/></arg><arg name="archivedate">17 November 2010<space/></arg><arg name="deadurl">no</arg></template></extension></part></link></paragraph><paragraph>The study of antibodies began in 1890 when<space/><link><target>Kitasato Shibasabur</target></link><space/>described antibody activity against<space/><link><target>diphtheria</target></link><space/>and<space/><link><target>tetanus toxin</target><trail>s</trail></link>. Kitasato put forward the theory of<space/><link><target>humoral immunity</target></link>, proposing that a mediator in serum could react with a foreign antigen.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-bio.html<space/></arg><arg name="title">Emil von Behring&nbsp;— Biography<space/></arg><arg name="accessdate"><space/>5 June 2007</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK0BRd1D<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>AGN<space/></arg><arg name="title"><space/>The Late Baron Shibasaburo Kitasato<space/></arg><arg name="journal"><space/>Canadian Medical Association Journal<space/></arg><arg name="year"><space/>1931<space/></arg><arg name="volume"><space/>25<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="page"><space/>206<space/></arg><arg name="pmc">382621<space/></arg><arg name="pmid">20318414</arg></template></extension><space/>His idea prompted Paul Ehrlich to propose the<space/><link><target>side-chain theory</target></link><space/>for antibody and antigen interaction in 1897, when he hypothesized that receptors (described as &quot;side-chains&quot;) on the surface of cells could bind specifically to<space/><link><target>toxin</target><trail>s</trail></link>&amp;nbsp; in a &quot;lock-and-key&quot; interaction&amp;nbsp; and that this binding reaction is the trigger for the production of antibodies.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Winau F, Westphal O, Winau R<space/></arg><arg name="title">Paul Ehrlich—in search of the magic bullet<space/></arg><arg name="journal">Microbes Infect.<space/></arg><arg name="volume">6<space/></arg><arg name="issue">8<space/></arg><arg name="pages">786–789<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">15207826<space/></arg><arg name="doi">10.1016/j.micinf.2004.04.003</arg></template></extension><space/>Other researchers believed that antibodies existed freely in the blood and, in 1904,<space/><link><target>Almroth Wright</target></link><space/>suggested that soluble antibodies coated<space/><link><target>bacteria</target></link><space/>to label them for<space/><link><target>phagocytosis</target></link><space/>and killing; a process that he named<space/><link><target>opsonin</target><trail>ization</trail></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Silverstein AM<space/></arg><arg name="title">Cellular versus humoral immunology: a century-long dispute<space/></arg><arg name="journal">Nat. Immunol.<space/></arg><arg name="volume">4<space/></arg><arg name="issue">5<space/></arg><arg name="pages">425–428<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">12719732<space/></arg><arg name="doi">10.1038/ni0503-425</arg></template></extension><link><target>File:Michael Heidelberger 1954.jpg</target><part>right</part><part>thumb</part><part>200px</part><part>Michael Heidelberger</part></link>In the 1920s,<space/><link><target>Michael Heidelberger</target></link><space/>and<space/><link><target>Oswald Avery</target></link><space/>observed that antigens could be precipitated by antibodies and went on to show that antibodies are made of protein.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Van Epps HL<space/></arg><arg name="title">Michael Heidelberger and the demystification of antibodies<space/></arg><arg name="journal">J. Exp. Med.<space/></arg><arg name="volume">203<space/></arg><arg name="issue">1<space/></arg><arg name="page">5<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16523537<space/></arg><arg name="url">http://www.jem.org/cgi/reprint/203/1/5.pdf<space/></arg><arg name="doi">10.1084/jem.2031fta<space/></arg><arg name="pmc">2118068</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK0EkKLx<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>The biochemical properties of antigen-antibody-binding interactions were examined in more detail in the late 1930s by<space/><link><target>John Marrack</target></link>.<extension extension_name='ref'><template><target>cite book</target><arg name="last"><space/>Marrack<space/></arg><arg name="first"><space/>JR<space/></arg><arg name="title"><space/>Chemistry of antigens and antibodies<space/></arg><arg name="edition"><space/>2nd<space/></arg><arg name="year"><space/>1938<space/></arg><arg name="publisher"><space/>His Majesty's Stationery Office<space/></arg><arg name="location"><space/>London<space/></arg><arg name="oclc">3220539</arg></template></extension><space/>The next major advance was in the 1940s, when<space/><link><target>Linus Pauling</target></link><space/>confirmed the lock-and-key theory proposed by Ehrlich by showing that the interactions between antibodies and antigens depend more on their shape than their chemical composition.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://profiles.nlm.nih.gov/MM/Views/Exhibit/narrative/specificity.html<space/></arg><arg name="title">The Linus Pauling Papers: How Antibodies and Enzymes Work<space/></arg><arg name="accessdate">5 June 2007</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uK0FQBmR<space/></arg><arg name="archivedate"><space/>17 November 2010</arg><arg name="deadurl">no</arg></template></extension><space/>In 1948, Astrid Fagreaus discovered that B cells, in the form of<space/><link><target>plasma cell</target><trail>s</trail></link>, were responsible for generating antibodies.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Silverstein AM<space/></arg><arg name="title"><space/>Labeled antigens and antibodies: the evolution of magic markers and magic bullets<space/></arg><arg name="journal"><space/>Nat. Immunol.<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1211–1217<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15549122<space/></arg><arg name="url"><space/>http://users.path.ox.ac.uk/~seminars/halelibrary/Paper%2018.pdf<space/></arg><arg name="doi"><space/>10.1038/ni1140</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5m6w1MlHG<space/></arg><arg name="archivedate"><space/>18 December 2009</arg><arg name="deadurl">no</arg></template></extension></paragraph><paragraph>Further work concentrated on characterizing the structures of the antibody proteins. A major advance in these structural studies was the discovery in the early 1960s by<space/><link><target>Gerald Edelman</target></link><space/>and Joseph Gally of the antibody<space/><link><target>Immunoglobulin light chain</target><part>light chain</part></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Edelman GM, Gally JA<space/></arg><arg name="title">The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins<space/></arg><arg name="journal">J. Exp. Med.<space/></arg><arg name="volume">116<space/></arg><arg name="issue"><space/>2</arg><arg name="pages"><space/>207–227<space/></arg><arg name="year">1962<space/></arg><arg name="pmid">13889153<space/></arg><arg name="doi">10.1084/jem.116.2.207<space/></arg><arg name="pmc">2137388</arg></template></extension><space/>and their realization that this protein is the same as the<space/><link><target>Bence-Jones protein</target></link><space/>described in 1845 by<space/><link><target>Henry Bence Jones</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Stevens FJ, Solomon A, Schiffer M<space/></arg><arg name="title">Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology<space/></arg><arg name="journal">Biochemistry<space/></arg><arg name="volume">30<space/></arg><arg name="issue">28<space/></arg><arg name="pages">6803–6805<space/></arg><arg name="year">1991<space/></arg><arg name="pmid">2069946<space/></arg><arg name="doi">10.1021/bi00242a001</arg></template></extension><space/>Edelman went on to discover that antibodies are composed of<space/><link><target>disulfide bond</target></link>-linked heavy and light chains. Around the same time, antibody-binding (Fab) and antibody tail (Fc) regions of IgG were characterized by<space/><link><target>Rodney Porter</target></link>.<extension extension_name='ref' name="edel"><template><target>cite journal</target><arg name="author">Raju TN<space/></arg><arg name="title">The Nobel chronicles. 1972: Gerald M Edelman (b 1929) and Rodney R Porter (1917–85)<space/></arg><arg name="journal">Lancet<space/></arg><arg name="volume">354<space/></arg><arg name="issue">9183<space/></arg><arg name="page">1040<space/></arg><arg name="year">1999<space/></arg><arg name="pmid">10501404<space/></arg><arg name="doi">10.1016/S0140-6736(05)76658-7</arg></template></extension><space/>Together, these scientists deduced the structure and complete<space/><link><target>amino acid</target></link><space/>sequence of IgG, a feat for which they were jointly awarded the 1972<space/><link><target>Nobel Prize in Physiology or Medicine</target></link>.<extension extension_name='ref' name="edel"></extension><space/>The Fv fragment was prepared and characterized by David Givol.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hochman J, Inbar D, Givol D<space/></arg><arg name="title">An active antibody fragment (Fv) composed of the variable portions of heavy and light chains<space/></arg><arg name="journal">Biochemistry<space/></arg><arg name="volume">12<space/></arg><arg name="issue"><space/>6</arg><arg name="pages">1130–1135<space/></arg><arg name="year">1973<space/></arg><arg name="pmid">4569769<space/></arg><arg name="doi"><space/>10.1021/bi00730a018</arg></template></extension><space/>While most of these early studies focused on IgM and IgG, other immunoglobulin isotypes were identified in the 1960s: Thomas Tomasi discovered secretory antibody (<link><target>IgA</target></link>)<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Tomasi TB<space/></arg><arg name="title">The discovery of secretory IgA and the mucosal immune system<space/></arg><arg name="journal">Immunol. Today<space/></arg><arg name="volume">13<space/></arg><arg name="issue">10<space/></arg><arg name="pages">416–418<space/></arg><arg name="year">1992<space/></arg><arg name="pmid">1343085<space/></arg><arg name="doi">10.1016/0167-5699(92)90093-M</arg></template></extension><space/>and David S. Rowe and John L. Fahey identified IgD,<extension extension_name='ref'><template><target>cite journal</target><arg name="author1">Preud'homme JL<space/></arg><arg name="author2">Petit I<space/></arg><arg name="author3">Barra A<space/></arg><arg name="author4">Morel F<space/></arg><arg name="author5">Lecron JC<space/></arg><arg name="author6">Lelièvre E<space/></arg><arg name="title">Structural and functional properties of membrane and secreted IgD<space/></arg><arg name="journal">Mol. Immunol.<space/></arg><arg name="volume">37<space/></arg><arg name="issue">15<space/></arg><arg name="pages">871–887<space/></arg><arg name="year">2000<space/></arg><arg name="pmid">11282392<space/></arg><arg name="doi">10.1016/S0161-5890(01)00006-2</arg></template></extension><space/>and<space/><link><target>IgE</target></link><space/>was identified by<space/><link><target>Kimishige Ishizaka</target></link><space/>and Teruko Ishizaka as a class of antibodies involved in allergic reactions.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Johansson SG<space/></arg><arg name="title">The discovery of immunoglobulin E<space/></arg><arg name="journal">Allergy and asthma proceedings : the official journal of regional and state allergy societies<space/></arg><arg name="volume">27<space/></arg><arg name="issue">2 Suppl 1<space/></arg><arg name="pages">S3–6<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16722325</arg></template></extension><space/>In a landmark series of experiments beginning in 1976,<space/><link><target>Susumu Tonegawa</target></link><space/>showed that genetic material can rearrange itself to form the vast array of available antibodies.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hozumi N, Tonegawa S<space/></arg><arg name="title">Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions<space/></arg><arg name="journal">Proc. Natl. Acad. Sci. U.S.A.<space/></arg><arg name="volume">73<space/></arg><arg name="issue">10<space/></arg><arg name="pages">3628–3632<space/></arg><arg name="year">1976<space/></arg><arg name="pmid">824647<space/></arg><arg name="pmc">431171<space/></arg><arg name="doi">10.1073/pnas.73.10.3628</arg></template></extension></paragraph><heading level='2'><link><target>Antibody mimetic</target></link></heading><paragraph>Antibody mimetics are organic compounds that, like antibodies, can specifically bind antigens. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa. Nucleic acids and small molecules are sometimes considered antibody mimetics, but not artificial antibodies, antibody fragments and fusion proteins are composed from these. Common advantages over antibodies are better solubility, tissue penetration, stability towards heat and enzymes, and comparatively low production costs. Antibody mimetics such as the<space/><link><target>Affimer</target><part>Affimer</part></link><space/>and the<space/><link><target>DARPin</target><part>DARPin</part></link><space/>have being developed and commercialised as research, diagnostic and therapeutic agents.<space/><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Gebauer M, Skerra A<space/></arg><arg name="title">Engineered protein scaffolds as next-generation antibody therapeutics<space/></arg><arg name="journal">Curr Opin Chem Biol<space/></arg><arg name="volume"><space/>13</arg><arg name="issue"><space/>3</arg><arg name="pages"><space/>245–255</arg><arg name="date">June 2009<space/></arg><arg name="pmid">19501012<space/></arg><arg name="doi">10.1016/j.cbpa.2009.04.627<space/></arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S1367-5931(09)00068-4</arg></template></extension></paragraph><heading level='2'>See also</heading><paragraph><template><target>colbegin</target><arg>3</arg></template></paragraph><list type='bullet'><listitem><link><target>Affimer</target></link></listitem><listitem><link><target>Antibody mimetic</target></link></listitem><listitem><link><target>Anti-mitochondrial antibodies</target></link></listitem><listitem><link><target>Anti-nuclear antibodies</target></link></listitem><listitem><link><target>Aptamer</target></link></listitem><listitem><link><target>Colostrum</target></link></listitem><listitem><link><target>ELISA</target></link></listitem><listitem><link><target>Humoral immunity</target></link></listitem><listitem><link><target>Immunology</target></link></listitem><listitem><link><target>Immunosuppressive drug</target></link></listitem><listitem><link><target>Intravenous immunoglobulin</target></link><space/>(IVIg)</listitem><listitem><link><target>Magnetic immunoassay</target></link></listitem><listitem><link><target>Microantibody</target></link></listitem><listitem><link><target>Monoclonal antibody</target></link></listitem><listitem><link><target>Neutralizing antibody</target></link></listitem><listitem><link><target>Secondary antibodies</target></link></listitem><listitem><link><target>Single-domain antibody</target></link></listitem><listitem><link><target>Slope spectroscopy</target></link></listitem></list><paragraph><template><target>colend</target></template></paragraph><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg name="refs">
<ref name</arg></template></paragraph><heading level='2'>External links</heading><paragraph><template><target>Commons category</target><arg>Antibodies</arg></template></paragraph><preblock><preline></preline><preline></preline><preline></preline><preline>*<space/><link type='external' href='http://www.path.cam.ac.uk/~mrc7/mikeimages.html'>Mike's Immunoglobulin Structure/Function Page</link><space/>at<space/><link><target>University of Cambridge</target></link></preline></preblock><list type='bullet'><listitem><link type='external' href='http://www.rcsb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/pdb21_1.html'>Antibodies as the PDB molecule of the month</link><space/>Discussion of the structure of antibodies at RCSB<space/><link><target>Protein Data Bank</target></link></listitem><listitem><link type='external' href='http://pathmicro.med.sc.edu/mayer/IgStruct2000.htm'>Microbiology and Immunology On-line Textbook</link><space/>at<space/><link><target>University of South Carolina</target></link></listitem><listitem><link type='external' href='http://users.path.ox.ac.uk/~scobbold/tig/new1/mabth.html'>A hundred years of antibody therapy</link><space/>History and applications of antibodies in the treatment of disease at<space/><link><target>University of Oxford</target></link></listitem><listitem><link type='external' href='http://www.cellsalive.com/antibody.htm'>How Lymphocytes Produce Antibody</link><space/>from Cells Alive!</listitem><listitem><link type='external' href='http://www.ii.bham.ac.uk/clinicalimmunology/CISimagelibrary/'>Antibody applications</link><space/>Fluorescent antibody image library,<space/><link><target>University of Birmingham</target></link></listitem></list><paragraph><template><target>immune system</target></template><template><target>Globular proteins</target></template><template><target>Immune proteins</target></template><template><target>Autoantibodies</target></template><template><target>good article</target></template><template><target>Use dmy dates</target><arg name="date">January 2011</arg></template></paragraph><paragraph><link><target>Category:Antibodies</target><part></part></link><link><target>Category:Glycoproteins</target></link><link><target>Category:Immune system</target></link><link><target>Category:Immunology</target></link></paragraph></article>